October 4th at 15:00
Hybrid event
Alhopuro Hall, Medisiina D

Gautier Follain, University of Turku
A closer look at the extravasation step of circulating tumor cells

On-line participation link: https://utu.zoom.us/j/65087190064
Passcode: 020919
Meeting ID: 650 8719 0064

Cancer Research Seminars are jointly organized by Turku Cancer Research Society TCRS, FICAN West and Cancer Research Unit/UTU

October 4th at 14:00
Virtual event

William Agace, Lund University and Danish Technical University
Intestinal dendritic cell diversity and function

October 4^th at 11:00
On-site event
Lauren 2, Medisiina D

Coffee, tea and sandwiches are served before the seminar

Aled Clayton, Cardiff University, UK
InFLAMES Visiting Professor career talk

InFLAMES also organizes an informal lunch meeting for early career scientists with Professor Clayton immediately after his career talk at 12 in Medisiina D Blokki 1. Please register separately for this event here: https://link.webropol.com/s/lunch-aled-clayton

Prof. Clayton established the first group focused on investigating the roles of extracellular vesicles (exosomes) in the UK. The group has published highly cited articles in relation to vesicles, their roles in subverting immune responses, in controlling the cancer microenvironment and as potential disease biomarkers. He has published some of the seminal articles of the EV field with a h-index of 45 (>18 000 citations).

He is interested in understanding the mechanisms by which vesicle biogenesis and secretion is controlled, and the impact such vesicles have on the development and progression of cancer; particularly focusing on prostate cancer. Developing tools and assays to quantify nano-vesicles in biological fluid specimens is also an important aspect of the group’s activities.

Although his main focus is in cancer biology, he collaborates broadly with researchers in Cardiff, including those in the schools of dentistry, engineering  and optometry, and interacts with other Universities on aspects including cardiovascular disease, neurodegenerative diseases and other conditions that impact society in significant ways.

https://www.cardiff.ac.uk/people/view/122903-clayton-aled

https://scholar.google.co.uk/citations?user=pgDjFGcAAAAJ&hl=en

September 28^th at 15:00
Virtual event in Teams

Juha Klefström, PhD, FICAN Research Professor in Finnish Cancer Institute
Uncovering the full potential of patient-derived explant cultures – exploring human breast cancer biology, lethal MYC signaling, microenvironment and antitumor immunity at the bench

Join the seminar: Teams link

Regional cancer centers have jointly started new national seminar series, the FICAN seminars. The second FICAN Seminar is organized by FICAN South (Eteläinen syöpäkeskus in Finnish) and the speaker is FICAN Research professor Juha Klefström from Finnish Cancer Institute. The seminar is organised in Teams and is open to all interested in the topic.

Get to know the Speaker:
https://klefstromlab.com/home/juha-klefstrom/

Abstract

Our research focuses on therapeutic strategies aiming to exploit oncogene-induced vulnerabilities and we have had a long-term interest especially in the apoptotic function of MYC protein. Our group recently discovered a clinically applicable combination regimen, which shows a strong apoptotic activity selectively in MYC-high breast tumors in all preclinical models tested so far. My talk will cover our advances in  translating the biological understanding of MYC biology into new type of therapeutic modalities to battle the breast cancer. A key asset in our research involves patient-derived explant culture models (PDEC) of breast cancer. We have pioneered the development of PDEC models and we have recently generated a whole family of PDEC models to explore for instance the biology of hormone receptor positive breast cancers, metastatic breast cancer microenvironment and drug resistance and possible ways to overcome. Furthermore, we have established a platform for PDECs with natural tumor infiltrating leukocytes to explore the immuno-oncology targeted drug responses. My talk will cover the latest developments in our work with PDEC models of breast cancer with specific focus on MYC-dependent signaling as a major cause of targetable vulnerabilities in breast cancer.

References

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Esserman LJ, van ‘t Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A.Nat Commun. 2022 Jun 27;13(1):3671. doi: 10.1038/s41467-022-31238-y.PMID: 35760778

Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Munne PM, Martikainen L, Räty I, Bertula K, Nonappa, Ruuska J, Ala-Hongisto H, Peura A, Hollmann B, Euro L, Yavuz K, Patrikainen L, Salmela M, Pokki J, Kivento M, Väänänen J, Suomi T, Nevalaita L, Mutka M, Kovanen P, Leidenius M, Meretoja T, Hukkinen K, Monni O, Pouwels J, Sahu B, Mattson J, Joensuu H, Heikkilä P, Elo LL, Metcalfe C, Junttila MR, Ikkala O, Klefström J.Nat Commun. 2021 Nov 29;12(1):6967. doi: 10.1038/s41467-021-27220-9.PMID: 34845227 Free PMC article.

Sortilin-related receptor is a druggable therapeutic target in breast cancer.
Al-Akhrass H, Pietilä M, Lilja J, Vesilahti EM, Anttila JM, Haikala HM, Munne PM, Klefström J, Peuhu E, Ivaska J.Mol Oncol. 2022 Jan;16(1):116-129. doi: 10.1002/1878-0261.13106. Epub 2021 Oct 10.PMID: 34564954 Free article.

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.
Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J.Nat Commun. 2019 Feb 6;10(1):620. doi: 10.1038/s41467-019-08541-2.PMID: 30728358 Free PMC article.

September 23^rd at 13:00
Virtual event in Zoom
Autumn 2022 program

Ville Paakinaho, PhD, Adj. Prof, University of Eastern Finland
Transcription Factor Crosstalk in Cancers

Rogerio De Figueiredo, Asst. Prof., PhD, University of Turku
The Future of Immune Checkpoint Therapies

Chair and opening words: Ammar Ahmedani

https://utu.zoom.us/j/64196971456

The Integrative Physiology and Pharmacology (IPP) seminar series is organized and coordinated by Juho-Antti Mäkelä (jasmak@utu.fi) and Noora Kotaja (nookot@utu.fi). We would like to encourage everybody to contact us if you or your supervisees want to give a presentation to share a great scientific story with the rest of us. Feedback is also always welcome. Attending these seminars is a great opportunity to get to better know the people around you and what they are doing.

.

September 13^th at 15:00
hybrid event
Medisiina D, Säätiö / Zoom

Jukka Westermarck, University of Turku
Translation of basic science findings to clinical use – Lessons from the sabbatical time in Milan

Welcome to the first Cancer Research Seminar of the fall season 2022! Cancer Research Special Seminar September the 13th, 2022, at 15-16:30, Medisiina D, first floor, Kiinamyllynkatu 10, Lecture room Säätiö “Translation of basic science findings to clinical use – Lessons from the sabbatical time in Milan” by Professor Jukka Westermarck, and discussion about the need and applications in Turku.

The seminar is arranged as a hybrid seminar.

Zoom link:
https://utu.zoom.us/j/67279196618
Meeting ID: 672 7919 6618
Passcode: 878028

Cancer Research Seminars are jointly organized by Turku Cancer Research Society and FICAN West

December 13th at 14:00
Virtual event

Luke O’Neill, Trinity College Dublin
Title  tba

Thursday June  6th

at 11-12

Säätiö-Sali (Medisiina D)

Professor Scott Allen from the University of Sheffield will be giving a lecture in Turku as a guest of InFLAMES. The lecture will be held on Thursday June 16^th in Medisiina D Säätiö-Sali, Med1024 at 11 am. The topic of the lecture is Mechanisms of glial toxicity contributing to neuronal damage.

There will be coffee, tea and sandwiches served on-site. You can also participate online in Zoom.

https://utu.zoom.us/j/61101388191

About Professor Scott Allen:

Professor Scott Allen is a neuroscientist from the University of Sheffield. He has worked on charting the basic mechanisms leading to the neural cell destruction via glial activation. The process is an important factor for example in ALS disease.

Thursday June  6th

at 11-12

Säätiö-Sali (Medisiina D)

Professor Scott Allen from the University of Sheffield will be giving a lecture in Turku as a guest of InFLAMES. The lecture will be held on Thursday June 16^th in Medisiina D Säätiö-Sali, Med1024 at 11 am. The topic of the lecture is Mechanisms of glial toxicity contributing to neuronal damage.

There will be coffee, tea and sandwiches served on-site. You can also participate online in Zoom.

https://utu.zoom.us/j/61101388191

About Professor Scott Allen:

Professor Scott Allen is a neuroscientist from the University of Sheffield. He has worked on charting the basic mechanisms leading to the neural cell destruction via glial activation. The process is an important factor for example in ALS disease.

June 10^th at 12:00
Medisiina D lecture hall Lauren 2

https://utu.zoom.us/j/66116584353

Welcome to the InFLAMES Visiting Professor lecture by Professor Teng-Leong Chew! The lecture is held on Friday, June 10^th at 14-15 in Medisiina D lecture hall Lauren 2. Coffee, tea and cookies are served on-site before the seminar.

It’s also possible to participate via Zoom:

https://utu.zoom.us/j/66116584353

Short biography of Professor Chew:

After obtaining a BS in Biochemistry at the University of Wisconsin-Madison, Teng-Leong Chew went to St. Louis University to pursue his PhD, where he worked to understand the role of myosin II regulation in endothelial cells. Realizing that conventional biochemical methods could not address the spatial and temporal regulation of signaling pathways inside the cell, Chew embarked on his postdoctoral research in the laboratory of Rex Chisholm by developing fluorescent biosensor to simultaneously monitor the enzymatic activity and localization pattern of myosin light chain kinase in vivo. Since then he has worked on multiple leading and directional positions, such as the director of the Center for Advanced Microscopy at Feinberg School of Medicine, Northwestern University.

Since 2014 Professor Chew has been the Director of Advanced Imaging Center (AIC), Howard Hughes Medical Institute, Janelia Research Campus), the leading institute in the world in the development of microscopy. He leads the effort in building the unique collaborative imaging center that serves as the gateway through which the wider scientific world can access Janelia’s cutting-edge microscopy capabilities. The AIC led by Dr Chew is an esteemed research centre in the world open to all researchers and the visiting research groups can use the instruments, cost-free. This infrastructure is not available anywhere else.

June 8th-10th
on-site event
BioCity, Presidentti auditorium

BioCity Turku research programme SmartBio is participating  in arranging a three-day congress

Elevating Nordic algal biotechnology: from fundamental photosynthesis to industry

The event will bring together excellent teams from academia and industry, and focuses on advances with cyanobacteria, micro-and macroalgae.

Registration, abstract submission and detailed program in
https://nas22.fi/

June 7^th at 14:00
Virtual event
Spring 2022 program

Marko Salmi, University of Turku
The lymph node as a filter

Registration latest Jun 6 at: https://link.webropolsurveys.com/S/38514ADFC0B3B229

Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.

Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience.

For further information contact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi), University of Turku.

Marko Salmi, MD, PhD, is currently Professor of Immunology at University of Turku. He also serves as Director of MediCity Research Laboratory, Director of Infection and Inflammation unit in Institute of Biomedicine and Vice-Director of InFLAMES Academy of Finland Flagship. Prof. Salmi’s research group studies myeloid cell differentiation, leukocyte migration and antigen transport in health and disease. The group has also analyzed the value of new biomarkers in inflammatory and malignant diseases using population and patient cohorts. Prof. Salmi has published >170 original research articles including senior-authorship papers in Immunity, Nature Immunology and Nature.

Selected publications

Rantakari P, Auvinen K, Jäppinen J, Kapraali M, Valtonen J, Karikoski M, Gerke H, , IIftakhar-E-Khuda I, Keuschnigg J, Umemoto E, Tohya K, Miyasaka M, Elima K, Jalkanen S, Salmi M. Plvap controls the entry of antigens to conduits and lymphocyte transmigration to parenchyma in the lymphatic sinus of lymph nodes. Nat Immunol 16:386-96, 2015.

Kähäri L, Fair-Mäkelä R, Auvinen K, Rantakari P, Jalkanen S, Ivaska J, Salmi M. Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. J Clin Invest. 129:3086-3102, 2019.

June 7^th–10^th
Hybrid event
Logomo

The 21st International European Light Microscopy Initiative (ELMI) meeting is coming back in 2022 as an in-person meeting held in Turku, Finland. ELMI 2022 will be a hybrid event, and a subset of the program, including the scientific presentation, will also be available online.

Final registration deadline: 16 May 2022

Register here: https://elmi2022.eu/registration-and-prices

ELMI 2022 will update you on the latest light microscopy developments, research, techniques, and instrumentation. During the morning sessions, international leaders will give plenary lectures. During the afternoon sessions, company workshops will provide demos of the latest microscopy techniques and instruments. ELMI 2022 will continue the successful tradition of bringing together microscopy users, developers, core facility staff, and industry leaders by mixing high-quality scientific talks and posters with workshops and demos of the latest imaging technologies, not forgetting social activities. This year the ELMI gala diner will be held in Naantali, a nearby city part of the Finnish archipelago and home of the Moomin island. As with previous ELMI meetings, we will also organize the traditional academia versus industry football game as well as a satellite meeting dedicated to core facility staff.

Consult the ELMI website for more information regarding the ELMI.

We hope many of you will join us in Turku for ELMI 2022.

June 7^th at 08:30
On-site event
Medisiina D, Lauren 1 and 2
Program

Many young researchers overlook that a PhD has a dual perspective:

1. To do good research and
2. To prepare you for your next career step whatever that might be. In this one-day career seminar, we aim at supporting you in seeing how you can prepare for your next career step, what the benefits are and how you can do it without taking your focus away from your research.

We will focus on increasing your understanding of the many skills you develop as a researcher, and how these are relevant both inside and outside of academia. You will hear speakers from different sectors discuss which skills are required in their areas, and you will work with mapping your own skill set. By the end of the day, you will hopefully have gained an awareness and understanding of the many important skills and experiences you develop as a young researcher, how these are highly useful and valued and in general understand how you can become a career-wise researcher. The day will be a mix of presentations and group work and coffee is included.

Registration is open until 30.5.2022 (23.59)
https://link.webropolsurveys.com/S/195EEF92BB2F8DDE

June 6^th at 12:00
Medisiina D lecture hall Lauren 2

https://utu.zoom.us/j/64085843903

Welcome to the introductory lecture of InFLAMES Visiting Professor Teng-Leong Chew! The lecture is held on Monday, June 6^th at 12-13 in Medisiina D lecture hall Lauren 2. Coffee, tea and cookies are served on-site before the seminar.

It’s also possible to participate via Zoom:

https://utu.zoom.us/j/64085843903

Short biography of Professor Chew:

After obtaining a BS in Biochemistry at the University of Wisconsin-Madison, Teng-Leong Chew went to St. Louis University to pursue his PhD, where he worked to understand the role of myosin II regulation in endothelial cells. Realizing that conventional biochemical methods could not address the spatial and temporal regulation of signaling pathways inside the cell, Chew embarked on his postdoctoral research in the laboratory of Rex Chisholm by developing fluorescent biosensor to simultaneously monitor the enzymatic activity and localization pattern of myosin light chain kinase in vivo. Since then he has worked on multiple leading and directional positions, such as the director of the Center for Advanced Microscopy at Feinberg School of Medicine, Northwestern University.

Since 2014 Professor Chew has been the Director of Advanced Imaging Center (AIC), Howard Hughes Medical Institute, Janelia Research Campus), the leading institute in the world in the development of microscopy. He leads the effort in building the unique collaborative imaging center that serves as the gateway through which the wider scientific world can access Janelia’s cutting-edge microscopy capabilities. The AIC led by Dr Chew is an esteemed research centre in the world open to all researchers and the visiting research groups can use the instruments, cost-free. This infrastructure is not available anywhere else.

May 25^th at 11:00-12:00
On-site event
Auditorium Biology, Biocity (2nd floor)

Asst. Prof. Tommaso Ristori, Eindhoven University of Technology
Computational modeling guides the research and control of angiogenesis
Host: Cecilia Sahlgren (cecilia.sahlgren@abo.fi)

Coffee, tea and pastries served at the start of the seminar

Dr. Ristori is an Assistant Professor in Biomedical Engineering at Eindhoven University of Technology, the Netherlands. His research is focused on computational modelling of angiogenesis for tissue engineering applications.

Achieving a full understanding and control of angiogenesis, the formation of new blood vessels from a pre-existing vasculature, is one of the key challenges to advance the field of tissue engineering. This process is regulated by several cross-talking cell signalling pathways, which vary over time and space. Perturbing their spatiotemporal dynamics is a promising recent trend in tissue engineering. Computational models can be a game-changer in this context; they can be combined with cell experiments to unravel the spatiotemporal interactions of different pathways and to optimize engineering techniques.

May 20^th at 13:00
virtual event
Spring 2022 prorgram

Petteri Rinne, PhD, Adj.Prof
Untangling the role of melanocortin signaling in the heart

Pekka Taimen, Asst. Prof., MD, PhD, University of Turku
Nuclear lamins and dilated cardiomyopathy

Chair and concluding remarks: Noora Kotaja

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

May 20^th at 13:00
virtual event
Spring 2022 prorgram

Petteri Rinne, PhD, Adj.Prof
Untangling the role of melanocortin signaling in the heart

Pekka Taimen, Asst. Prof., MD, PhD, University of Turku
Nuclear lamins and dilated cardiomyopathy

Chair and concluding remarks: Noora Kotaja

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

May 18^th at 12:00
Hybrid event
Medisiina D, Lauren / Zoom

Welcome to join us for the early life environment and child development spring seminar by international researchers visiting the FinnBrain Birth Cohort Study. The seminar will take place on 18th of May, 2022 at 12 – 2 pm, Lauren auditorium, Medisiina D, Kiinanmyllynkatu 10, University of Turku.

The seminar can also be followed remotely: https://utu.zoom.us/j/61482726079

May 12^th-13^th
On-site event
Institute of Dentistry, Arje Scheinin Hall

We cordially invite you to attend the FINDOS symposium Inflammatory Conditions and their effects on Oral and General Health. We proudly present a versatile programme with great speakers and current topics. See the programme attached and at https://sites.utu.fi/findos-symposiums/findos-symposium-2022/

Participation in FINDOS Symposium 2022 is free of charge. Coffee and pastries are available during the coffee breaks. Conference lunch is not included. The symposium is organized only in person to facilitate networking. No hybrid nor recordings are available.

The deadline for registration is 28 April 2022. Register now!
https://link.webropolsurveys.com/S/3DDBBAFB7CE653B0

Digital poster exhibition

This year FINDOS Symposium digital poster session will be organized as “Read by title” presentations. All National FINDOS doctoral candidates and other researchers and research groups are invited to send their digital posters in PowerPoint presentation form that could be presented as “a read by title” presentation. The presentation will be viewable as a power point presentation on the spot on screen during the breaks. The presentations are running automatically on the screens but it is recommended that the researcher could be at the place on Thursday 12 May 2022 at 11.00-11.30 in Arje Schein lecture hall for questions and discussions with other researchers.

Instructions

The presentation should not include more than 3 slides.

The opening slide should display a straightforward title, name of the researcher and collaborators, affiliations and some attractive image. The objective, materials, and methods, results and conclusions should not exceed more than 250 words, and they should be presented in maximum of 2 slides.

Clinical patient cases can also be presented.

Submission of Posters (ppt) by 4 May 2022 to Coordinator Maiju Kannisto maiju.kannisto@utu.fi

We strongly encourage all study groups and researchers to present their studies in FINDOS Symposium!

If you want more information about the presentations, please contact Jaana Willberg jaana.willberg@utu.fi

Welcome!

May 12^th-13^th
On-site event
Institute of Dentistry, Arje Scheinin Hall

We cordially invite you to attend the FINDOS symposium Inflammatory Conditions and their effects on Oral and General Health. We proudly present a versatile programme with great speakers and current topics. See the programme attached and at https://sites.utu.fi/findos-symposiums/findos-symposium-2022/

Participation in FINDOS Symposium 2022 is free of charge. Coffee and pastries are available during the coffee breaks. Conference lunch is not included. The symposium is organized only in person to facilitate networking. No hybrid nor recordings are available.

The deadline for registration is 28 April 2022. Register now!
https://link.webropolsurveys.com/S/3DDBBAFB7CE653B0

Digital poster exhibition

This year FINDOS Symposium digital poster session will be organized as “Read by title” presentations. All National FINDOS doctoral candidates and other researchers and research groups are invited to send their digital posters in PowerPoint presentation form that could be presented as “a read by title” presentation. The presentation will be viewable as a power point presentation on the spot on screen during the breaks. The presentations are running automatically on the screens but it is recommended that the researcher could be at the place on Thursday 12 May 2022 at 11.00-11.30 in Arje Schein lecture hall for questions and discussions with other researchers.

Instructions

The presentation should not include more than 3 slides.

The opening slide should display a straightforward title, name of the researcher and collaborators, affiliations and some attractive image. The objective, materials, and methods, results and conclusions should not exceed more than 250 words, and they should be presented in maximum of 2 slides.

Clinical patient cases can also be presented.

Submission of Posters (ppt) by 4 May 2022 to Coordinator Maiju Kannisto maiju.kannisto@utu.fi

We strongly encourage all study groups and researchers to present their studies in FINDOS Symposium!

If you want more information about the presentations, please contact Jaana Willberg jaana.willberg@utu.fi

Welcome!

May 6^th at 13:00
virtual event
Spring 2022 prorgram

Nafis Rahman, MD, PhD, Adj. Prof:
Molecular mechanisms underlying selective progesterone receptor modulator mifepristone’s agonistic action on ovarian cancer progression

Elisa Närvä, PhD, Adj. Prof, University of Turku
Kinase-independent role of MASTL in breast cancer and in stemness

Chair: Matthieu Bourgery

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

May 3rd at 14:00 – 15:00
Virtual event

Ludvig Sollid, Institute of Clinical Medicine and KG Jebsen Coeliac Disease Research Centre, University of Oslo and Department of Immunology, Oslo University Hospital: “
Triggers and drivers of autoimmunity

Registration latest May 2nd at: https://link.webropolsurveys.com/S/E8E36C4960A8B012

Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.

Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience. For further information contact Anne Lahdenperä ( ankahy@utu.fi ) or Riitta Lahesmaa ( rilahes@utu.fi ), University of Turku.

Ludvig M. Sollid (MD, PhD) is a Professor at the University of Oslo and a Senior Consultant at the Oslo University Hospital – Rikshospitalet. He is also the Director of the KG Jebsen Coeliac Disease Research Centre and UiO FOCIS Centre of Excellence. His research interests are focused around genetics and immunology of autoimmune diseases.

His group has made important contributions to the understanding of the molecular basis of coeliac disease, in particular the role of HLA genes, the existence of gluten reactive (HLA-DQ restricted) T cells in the coeliac intestinal lesion, the identification of immunotoxic gluten peptide sequences and the involvement of the transglutaminase 2 in the pathogenesis of the disease. His group is currently working on the characterization of the antigen receptors of T cells and B cells that recognize the coeliac disease relevant antigens gluten and transglutaminase 2.

Sollid is the recipient of several research awards including the Research Council of Norway’s Møbius Prize for Outstanding Research, the Warren Prize for Excellence in Celiac Disease Research, the Rank Prize in Nutrition, the UEG Research Prize and the Jahre Medical Prize (junior award 1998 and senior award (2015). He currently serves on the editorial boards of Mucosal Immunology, Scandinavian Journal of Immunology, Tissue Antigens, Genes and Immunity and Gastroenterology.

Selected publications

Ludvig M Sollid, Bana Jabri. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol 13:294-302, 2013.

Ludvig M Sollid. Epstein-Barr virus as a driver of multiple sclerosis. Sci Immunol. 7:eabo7799, 2022.

Roberto Di Niro, Luka Mesin, Nai-Ying Zheng, Jorunn Stamnaes, Michael Morrissey, Jane-Hwei Lee, Min Huang, Rasmus Iversen, M Fleur du Pré, Shuo-Wang Qiao, Knut E A Lundin, Patrick C Wilson, Ludvig M Sollid.

High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med 18:441-5, 2012.

Asbjørn Christophersen, Eivind G Lund, Omri Snir, Elsa Solà, Chakravarthi Kanduri, Shiva Dahal-Koirala, Stephanie Zühlke, Øyvind Molberg, Paul J Utz, Mina Rohani-Pichavant, Julia F Simard, Cornelia L Dekker, Knut E A Lundin, Ludvig M Sollid, Mark M Davis. Distinct phenotype of CD4 + T cells driving celiac disease identified in multiple autoimmune conditions. Nat Med 25:734-737, 2019.

M Fleur du Pré, Jana Blazevski, Alisa E Dewan, Jorunn Stamnaes, Chakravarthi Kanduri, Geir Kjetil Sandve, Marie K Johannesen, Christian B Lindstad, Kathrin Hnida, Lars Fugger, Gerry Melino, Shuo-Wang Qiao, Ludvig M Sollid. B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2. J Exp Med 217:e20190860, 2020.

May 3rd at 14:00
hybrid event
Alhopuro hall / Zoom

New Cutting-Edge Methods in Cancer Research

14.00 Tapio Lönnberg “Single-cell and spatially resolved sequencing approaches to explore tissue composition”
14.20 Pia Rantakari “Spatial image analysis with Imagine mass cytometry”
14.40 Pekka Ruusuvuori “Quantitative analysis of multiplex stained tissue”
15.00 Coffee Break
15.15 Johanna Lilja “Multiplex Immunofluorescence Imaging to explore tissue spatial organization”
15.35 Emilia Peuhu “Spatial tissue engineering with 3D bioprinting”
15.55 Otto Kauko “Mass spectrometry-based proteomics in cancer research”

REGISTRATION
Only for those attending on-site at Alhopuro hall:
https://link.webropolsurveys.com/S/EA289CC2172B96F2

Join Zoom Meeting: https://utu.zoom.us/j/66586666315
Passcode: 010040

April 29^th at 09:00
Virtual event
Program

The universities in Turku, in close collaboration with Turku Science Park, have launched a joint Aboa Tech Talks webinar series focusing on emerging technologies and sustainable development. Aboa Tech Talks aims to highlight advanced and innovative technological research and education carried in the universities that can offer sustainable solutions to the complex global challenges of our time. The topic of this webinar is sustainable shipping.

Aboa Tech Talks – Sustainable Shipping is an online event and it is free of charge and open to anyone interested, including representatives from industry, government, the third sector, researchers and students. The event’s language is English and it is held in Teams. You will receive a link to the event after registration. Novia UAS, Campus Aboa Mare will moderate the event.

Registration and detailed program

Sari Repka, University of Turku
Pursuit of zero-emission shipping

Magnus Gustafsson, Åbo Akademi University
Business models for decarbonizing shipping

Jari M. Lahtinen, Turku University of Applied Sciences
Management of The Ship Environmental Load

Magnus Winberg, Novia University of Applied Sciences / Aboa Mare
Sustainable development in maritime education & training

Dani Lindberg, Viking Line Abp
Sustainable Shipping in the Baltic Sea and Viking Glory

Apri 27^th at 11:15
Virtual event only

Adj. Prof Maria Lankinen, Institute of Public Health and Clinical Nutrition, UEF
Gene-diet interactions in polyunsaturated fatty acid metabolism and inflammation

Host: Kirsi Laitinen

https://utu.zoom.us/j/7562392825

April 22^nd at 13:00
virtual event
Spring 2022 prorgram

Pieta Mattila, PhD, Adj. Prof, University of Turku
Dissecting early B cell activation with microscopic and proteomic tools

Hanna Heikelä, MSc (MP)
HSD17Bs in steroid and lipid metabolism and lipid disorders: The role of HSD17B12 and HSD17B13

Chair: Noora Houttu

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

April 13th at 11:15
Hybrid event
Medisiina D, Säätiö / Zoom

Jukka Alinikula
Somatic hypermutation of antibody genes and beyond

Zoom details for virtual participants:
https://utu.zoom.us/j/7562392825

Program for all spring 2022 Infections and Immunity Seminars

April 5th at 15:00
hybrid event
Alhopuro hall / Zoom

TCRS Young PI Award 2021 Lectures

Hongbo Zhang
Solution for Health with Functional Materials

Guillaume Jacquemet
Studying cancer cell metastases in the era of Deep Learning for microscopy

Join Zoom Meeting: https://utu.zoom.us/j/66586666315
Passcode: 010040

April 5^th at 14:00
Virtual event
Spring 2022 program

Bernard Malissen, Centre d’Immunologie de Marseille-Luminy, France
Quantitative interactomics of the TCR signal-transduction network and of its co-inhibitors
Flyer

Registration latest Apr 4 at: https://link.webropolsurveys.com/S/DABCBD92434374D1

Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.

Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience.

For further information contact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi), University of Turku.

Bernard Malissen is the Founding-Director of the Center for Immunophenomics (Marseille, France; https://ciphe.marseille.inserm.fr/en/ ) and Director of the Team ‘Integrative Biology of T cells and Dendritic cells’ at Centre d’Immunologie de Marseille Luminy (http://www.ciml.univ-mrs.fr/science/lab-bernard-marie-malissen/home ). Bernard Malissen pioneered in the eighties the use of gene transfer approaches to dissect the function of Major Histocompatibility Complex (MHC) molecules. He also succeeded reconstructing a full T cell antigen receptor (TCR) complex and demonstrated that the present-day signaling subunits associated with antigen receptors stem from a common primordial building block. He provided the first evidence for chromosomal inversion during TCR gene rearrangements. His team was also the first to elucidate the atomic structure of an alloreactive TCR in complex with its peptide-MHC ligand, providing a molecular explanation for the basis of transplant rejection and contributing to unveil the structural basis of TCR binding-degeneracy. His recent interests extend to dendritic cells and macrophages, leading his team to disentangle their functional complexity in the skin. To make sense of the formidable complexity of the signal transduction networks involved in T cell activation, he recently combined “omic” approaches that measure large numbers of parameters and genetic screens. His recent work provided a systems level picture of the TCR signal transduction network and of its tuning by costimulatory and coinhibitory receptors. Such systems-level approaches highlighted the conservation and dissimilarities between human and mouse T cells.

Selected publications

Nicolas, P., J. Ollier, D. Mori, G. Voisinne, J. Celis-Gutierrez, C. Gregoire, J. Perroteau, R. Vivien, M. Camus, O. Burlet-Schiltz, A. Gonzalez de Peredo, B. Clemenceau, R. Roncagalli, H. Vie, and B. Malissen. 2022. Systems-level conservation of the proximal TCR signaling network of mice and humans. J Exp Med 219: e20211295

Voisinne, G., K. Kersse, K. Chaoui, L. Lu, J. Chaix, L. Zhang, M. Goncalves Menoita, L. Girard, Y. Ounoughene, H. Wang, O. Burlet-Schiltz, H. Luche, F. Fiore, M. Malissen, A. Gonzalez de Peredo, Y. Liang, R. Roncagalli, and B. Malissen. 2019. Quantitative interactomics in primary T cells unveils TCR signal diversification extent and dynamics. Nat Immunol 20:1530-1541.

Celis-Gutierrez, J., P. Blattmann, Y. Zhai, N. Jarmuzynski, K. Ruminski, C. Gregoire, Y. Ounoughene, F. Fiore, R. Aebersold, R. Roncagalli, M. Gstaiger, and B. Malissen. 2019. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep 27:3315-3330 e3317.

Mori, D., C. Gregoire, G. Voisinne, J. Celis-Gutierrez, R. Aussel, L. Girard, M. Camus, M. Marcellin, J. Argenty, O. Burlet-Schiltz, F. Fiore, A. Gonzalez de Peredo, M. Malissen, R. Roncagalli, and B. Malissen. 2021. The T cell CD6 receptor operates a multitask signalosome with opposite functions in T cell activation. J Exp Med 218: e20201011

April 1^st at 13:00
virtual event
Spring 2022 prorgram

Riku Klén, Asst. Prof., PhD, University of Turku
Predictive models in cardiac research

Pia Rantakari, PhD, Adj. Prof, University of Turku
A new view of macrophages in endocrine tissues

Chair: Guillermo Martinez-Nieto

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

March 31^st at 13:30
on-site event in Aurum, Auditorium Argentum

Open doors at Aurum, Biomaterial research infra in Aurum and junior researcher networking
Hosts: Chunlin Xu (cxu@abo.fi) and Leena Hupa (leena.hups@abo.fi)

The aim is to promote interactive activities within Biomaterials and Medical Devices research programme. We hope that by arranging this networking event researchers, particularly junior ones (PhD students and postdocs), can meet and brainstorm cooperative ideas.

The proposed agenda
13:30                  gathering and coffee
14:00                  introduction (who, which research unit, research topics and interests), Auditorium Argentum
14:30                  short introduction to Aurum and research activities in Aurum 14:30, lab tours

Please register latest 27.3. by sending email to cxu@abo.fi

Welcome!

March 30th at 11:30
Hybrid event
Medisiina D, Säätiö / Zoom

Adjunct professor Maria Lankinen, Institute of Public Health and Clinical Nutrition, UEF
Gene-diet interactions in polyunsaturated fatty acid metabolism and inflammation
host: Kirsi Laitinen

Zoom details for virtual participants:
https://utu.zoom.us/j/7562392825

Program for all spring 2022 Infections and Immunity Seminars

March 24th at 14:00
virtual event

In collaboration with the InFLAMES Flagship Meso Scale Discovery (MSD) invites you to introduction webinar on Multiplex immunoassay platform. The webinar will give an introduction to validated and flexible multiplex assays for biomarkers in several research fields such as inflammation, neuro, diabetes, cancer and so on. Since it is an open platform you may also use it for ADA, PK assays, ELISA conversion and more. At the moment MSD SARS- CoV2 panels, including both wild type and different variants are highly used world wide.

Register by email to receive a link to the webinar: Eva Ludvigsen, eludvigsen@mesoscale.com, +46 70 3790433

March 18^th at 13:00
virtual event
Spring 2022 prorgram

Vappu Nieminen-Pihala, MSc (RK)
Transcription factors Ebf1 and Ebf2 in bone metabolism

Riikka Huhtaniemi, MSc (MP)
Androgen receptor related therapy resistance in prostate cancer: From disease model to mechanisms

Chair: Mehrad Mahmoudian

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

CANCELLED

March 16th at 10:15
Hybrid event
Medisiina D, Säätiö / Zoom

Eeva-Liisa Eskelinen
Membrane dynamics during autophagosome formation and maturation

Zoom details for virtual participants:
https://utu.zoom.us/j/7562392825

Program for all spring 2022 Infections and Immunity Seminars

virtual event

Deepankar Chakroborty
Developing a high-throughput screen to identify activating mutations in tyrosine kinases

Eva-Maria Talvitie
A high number of targetable genomic alterations in lung adenocarcinoma in a Southwestern Finnish population

Cancer Research Seminar Series – organized by Turku Cancer Research Society and FICAN West

Zoom details to join the seminar
https://utu.zoom.us/j/66586666315
Meeting ID: 665 8666 6315
Passcode: 010040

March 4^th at 13:00
virtual event
Spring 2022 prorgram

Adj. Prof. Renata Prunskaite-Hyyryläinen, University of Oulu
Novel testes gene function in spermatogenesis and 3D uterine morphology

Adj. Prof. Kaisa Ivaska-Papaioannou
Insights into bone marrow adiposity in metabolic disorders

Chair: Ella Koivuniemi

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

March 2nd at 11:15
Hybrid event
Medisiina D, Säätiö / Zoom

Pieta Mattila
Dissecting early B cell activation with microscopic and proteomic tools

Zoom details for virtual participants:
https://utu.zoom.us/j/7562392825

Program for all spring 2022 Infections and Immunity Seminars

March 1^st at 14:00
Virtual event
Spring 2022 program

Heikki Hyöty, Tampere University
Type 1 diabetes, enterovirus and prospects of vaccine development
Flyer

Registration latest Feb 28 at https://link.webropolsurveys.com/S/64C9EC43374D8B69

Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.

Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience.

For further information contact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi), University of Turku.

Dr. Heikki Hyöty is Professor of Virology at Tampere University, Faculty of Medicine and Health Technology since 2013. Prof. Hyöty has received his PhD in virology in 1989. He has served as Professor of Biomedicine and Virology at University of Tampere prior to his current position. Prof. Hyöty leads a virology group that studies the role of viruses and other microbes in immune-mediated diseases including type 1 diabetes, asthma, allergy and celiac disease. The group has studied  microbe-disease associations in prospective cohorts and translated innovations to develop new treatments and better diagnostics. One major initiative is the project developing an enterovirus vaccine that could prevent severe enterovirus diseases and type 1 diabetes. This project has generated a vaccine against Coxsackie B viruses which have been linked to type 1 diabetes. Professor Hyöty is coordinator of four EU funded projects, and has 422 original articles and altogether nine patents/patent applications.

Selected publications

Sioofy-Khojine AB, Lehtonen J, Nurminen N, Laitinen OH, Oikarinen S, Huhtala H,  Pakkanen O, Ruokoranta T, Hankaniemi MM, Toppari J, Vähä-Mäkilä M, Ilonen J, Veijola R, Knip M, Hyöty H. Coxsackievirus B infections are associated with the initiation of insulin-driven autoimmunity that progress to type 1 diabetes. Diabetologia 6:1193-1202, 2018.

Hyöty H, Leon F, Knip M. Developing a vaccine for Type 1 diabetes by targeting coxsackievirus B. Expert Rev Vaccines. 17(12):1071-1083, 2018.

Vehik K, Lynch KF, Wong MC, Tian X, Ross MC, Gibbs RA, Ajami NJ, Petrosino JF,  Rewers M, Toppari J, Ziegler AG, She JX, Lernmark A, Akolkar B, Hagopian WA, Schatz DA, Krischer JP, Hyöty H, Lloyd RE, and the TEDDY Study Group. Prospective virome analyses reveals prolonged enterovirus B shedding precedes islet autoimmunity in children at increased genetic risk for type 1 diabetes. Nat Med. 25(12):1865-1872, 2019.

Stone VM, Butrym M, Hankaniemi MM, Sioofy-Khojine A-B, Hytönen VP, Hyöty H, Flodström-Tullberg M. Coxsackievirus B vaccines prevent infection-accelerated diabetes in NOD mice and have no disease-inducing effect. Diabetes 70(12):2871-2878, 2021.

Oikarinen S, Krogvold L, Edwin B, Buanes T, Korsgren O, Laiho JE, Oikarinen M, Ludvigsson J, Skog O, Anagandula M, Frisk G, Hyöty H*, Dahl-Jørgensen K*. Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia 64(11):2491-2501, 2021.

February 18^th at 13:00
on-site event
Arje Scheinin auditorium, Dentalia
Spring 2022 prorgram

Ilpo Huhtaniemi
Good and bad testosterone

Chair: Nafis Rahman

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

February 17th at 11:15
Virtual event

Arno Hänninen
Microbiota and gut immune system in infancy and in autoimmune disease

Zoom details:
https://utu.zoom.us/j/7562392825

Program for all spring 2022 Infections and Immunity Seminars

February 17^th at 09:30
Virtual event
Flyer
Program

The increasing use of renewable wind and solar energy will result in variations in the energy supply, depending on weather conditions and time of the day. Sustainable energy storage solutions will be needed to balance such variations. Join the webinar to learn more about the emerging technical solutions in academia and industry.

Speakers
Anne Nordström, TUAS, opening words
Henrik Saxén, ÅAU, A review of electrical energy storage
Pekka Peljo, UTU, Pathways towards sustainable stationary energy storage
Osmo Huhtala, TUAS, LVDC microgrids with renewable energy sources
Rainer Nurkkala, Elcon Solutions Oy, Battery system for positive energy district

More details about the event:
https://www.turkuamk.fi/fi/tapahtumat/1081/aboa-tech-talks-sustainable-energy-storage-solutions/

Register via Lyyti:
https://www.lyyti.fi/reg/Aboa_Tech_Talks_Sustainable_Energy_Storage_Solutions_4448

Welcome!

virtual event

Sara Zanivan, Cancer Research UK
Cancer associated fibroblasts: the architects of tumour stroma remodeling
Host: Elisa Närvä

Cancer Research Seminar Series – organized by Turku Cancer Research Society and FICAN West

Zoom details to join the seminar
https://utu.zoom.us/j/66586666315
Meeting ID: 665 8666 6315
Passcode: 010040

February 9^th at 13:00
Virtual event

Article to be presented:
“Confronting false discoveries in single-cell differential expression”
https://www.nature.com/articles/s41467-021-25960-2

Please join the meeting in Zoom: https://utu.zoom.us/j/69319211252

Medical Bioinformatics Centre (MBC) welcomes everybody to the Bioinformatics Journal Club, where the aim is to get to know the latest development in the bioinformatics field and how bioinformatics solutions help advance biomedical research. Students have an opportunity to earn 1-5 ECTS credits by presenting and participating in the Bioinformatics Journal Club. Journal Club will be held once a month during Spring 2022.

February 4^th at 13:00
Virtual event
Spring 2022 prorgram

Adj. Prof, Emilia Peuhu, University of Turku
Form follows function – Investigation of breast epithelial mechanics

Asst. Prof, Marie Lagerquist, University of Gothenburg, Sweden
Tissue-specific effects of membrane-initiated estrogen receptor alpha signaling

Chair and opening words: Matti Poutanen

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Zoom link to join the seminar:
https://utu.zoom.us/s/68303022462

February 2^nd at 11:15
Hybrid event
Medisiina D, Skooppi 1+2 / Zoom

Teemu Smura, Department of Virology, University of Helsinki
How to sequence (Corona)viruses
host: Petri Susi

Zoom details for virtual participants:
https://utu.zoom.us/j/7562392825

Program for all spring 2022 Infections and Immunity Seminars

February 1^st at 14:00
Virtual event
Spring 2022 program

Jenny Mjösberg, Karolinska Institutet
Tissue- and inflammation-specific imprinting of human innate lymphoid cells
Flyer

Registration latest Jan 31 at: https://link.webropolsurveys.com/S/60ED5C13513358D0

Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.

Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience.

For further information contact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi), University of Turku.

Jenny Mjösberg is an associate professor at the Center for Infectious Medicine (CIM), Karolinska Institutet, Stockholm, Sweden. She earned her PhD in reproductive immunology at Linköping University, Sweden, in 2010. During her postdoc period in the lab of Hergen Spits at the AMC, Amsterdam, she contributed to the discovery of two novel subsets of human ILCs; ILC2 and ILC1. Since 2013, research in her own lab at CIM is focused on the importance of human ILCs in mucosal homeostasis and inflammation, mainly in the lung and gastrointestinal tract. Importantly, in 2016 Mjösberg provided the first transcriptional characterization of human ILCs on the single-cell level. These studies, along with continued transcriptional and epigenetic dissection of ILCs across several human organs have revealed previously unknown heterogeneity and a plethora of characteristics and regulatory mechanisms that control the function of specific ILC subsets. Her group ultimately aims at understanding the role of ILCs in asthma and gastrointestinal disease, including colorectal cancer and inflammatory bowel disease, for the development of novel therapeutic concepts.

Selected publications

1. Mazzurana L, Czarnewski P, Jonsson V, Wigge L, Ringnér M, Williams TC, Ravindran A, Björklund ÅK, Säfholm J, Nilsson G, Dahlén SE, Orre AC, Al-Ameri M, Höög C, Hedin C, Szczegielniak S, Almer S, Mjösberg J. Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNA-sequencing. Cell Res. 2021 Jan 8. doi: 10.1038/s41422-020-00445-x.
2. Rao A, Strauss O, Kokkinou E, Bruchard M, Tripathi KP, Schlums H, Carrasco A, Mazzurana L, Konya V, Villablanca EJ, Björkström NK, Lindforss U, Spits H, Mjösberg J. Cytokines regulate the antigen-presenting characteristics of human circulating and tissue-resident intestinal ILCs. Nat Commun. 2020 Apr 27;11(1):2049.
3. Maric J, Ravindran A, Mazzurana L, Björklund ÅK, van Acker A, Rao A, Kokkinou E, Ekoff M, Thomas D, Fauland A, Nilsson G, Wheelock CE, Dahlén E, Ferreirós N, Geisslinger G, Friberg D, Heinemann A, Konya V and Mjösberg J. Cytokine-induced endogenous production of PGD2 is essential for human ILC2 activation. J Allergy Clin Immunol (JACI). 2019 Jun; 143(6):2202-2214.
4. Konya V, Czarnewski P, Rao A, Forkel M, Villablanca E, Almer S, Lindforss U, Friberg D, Höög C, Bergman P and Mjösberg J. Vitamin D downregulates the IL-23 receptor pathway in human mucosal ILC3. J Allergy Clin Immunol (JACI). 2018 Jan; 141(1):279-292.
5. Björklund ÅK, Forkel M, Picelli S, Konya V, Theorell J, Friberg D, Sandberg R, Mjösberg J. The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA-sequencing. Nat Immunol. 2016. 17(4):451-60.

January 19^th at 11:15
Hybrid event
Medisiina D, Säätiö / Zoom

Sirpa Jalkanen
InFLAMES Research Flagship – Solution is in Immunity

Zoom details for virtual participants:
https://utu.zoom.us/j/7562392825

Program for all spring 2022 Infections and Immunity Seminars

16.12.2021 at 18–19
President auditorium, BioCity
Hybrid event
Flyer

Glögi and cookies will be served at 17.30

Prof. Dr. Lude Franke, Department of Genetics, University Medical Centre Groningen, Netherlands
Towards personalised, directed gene regulatory networks for better understanding common and rare diseases
Host: Riitta Lahesmaa (rilahes@utu.fi)

Register latest December 14th
https://link.webropolsurveys.com/S/7CBE4205F5B0DBC4

Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.
Please note: If you participate the seminar in President auditorium, be prepared to show a COVID-19 passport and ID.

Special Guest Seminar is jointly organised by InFLAMES Flagship, Lifespan research program and Turku Bioscience. For further information contact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi), University of Turku.

Dr. Lude Franke is Full Professor of Functional Genomics in the Department of Genetics, University Medical Centre Groningen, where he guides his group on multi-omics data generation and analysis. His research group focuses in the development of computational methods to identify the downstream molecular effects of these disease-associated genetic variants.

The research line that he has set out over the last years involves the development and application of computational algorithms to functional genomics datasets. Lude Franke’s group is currently concentrating on integrating large-scale multi-omics datasets by conducting large-scale trans-QTL meta-analyses in >30,000 samples (Vosa et al, BioRxiv 2018) in conjunction with single-cell RNA-seq data (Van der Wijst et al, Nature Genetics 2018) with the principal aims to conduct eQTL meta-analysis and to reconstruct personalized regulatory networks that can be used to better understand disease-associated genetic variants. To do this optimally, they have initiated the single-cell eQTL consortium where >20 international research groups work towards a large-scale federated cell-type specific eQTL analysis in >3,000 samples and reconstruction of cell-type specific gene regulatory networks (Van der Wijst, eLife 2020).

Most recently, Lude Franke has initiated and leads the Lifelines COVID19 research project and accompanying CoronaBarometer website, a questionnaire-based study in 167,000 Lifelines biobank participants with the aim to contribute to the identification of risk factors for COVID19 susceptibility and severity, and to longitudinally study the impact of the COVID19 pandemic on the well-being of Dutch citizens.

Lude Franke has also received many prestigious grants such as  VENI, VIDI, VICI, Oncode and ERC Starting Grants and he helds membership of the Young Academy (de Jonge Akademie, KNAW).

Relevant papers

1. Large-scale cis-and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Urmo Võsa, Annique Claringbould, Harm-Jan Westra, Marc Jan Bonder, Patrick Deelen, …, Markus Scholz, Joseph Powell, Greg Gibson, Tõnu Esko, Lude Franke. Nat Genet. 2021 Sep;53:1300–1310
2. Single-cell RNA sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs. van der Wijst MGP, Brugge H, de Vries DH, Deelen P, Swertz MA; LifeLines Cohort Study; BIOS Consortium, Franke L. Nat Genet. 2018 Apr;50(4):493-497.
3. Disease variants alter transcription factor levels and methylation of their binding sites. BonderMJ, Luijk R, Zhernakova DV, Moed M, Deelen P, Vermaat M, van Iterson M, van Dijk F, van Galen M, Bot J, Slieker RC, Jhamai PM, Verbiest M, Suchiman HE, Verkerk M, van der Breggen R, van Rooij J, Lakenberg N, Arindrarto W, Kielbasa SM, Jonkers I, van ‘t Hof P, Nooren I, Beekman M, Deelen J, van Heemst D, Zhernakova A, Tigchelaar EF, Swertz MA, Hofman A, Uitterlinden AG, Pool R, van Dongen J, Hottenga JJ, Stehouwer CD, van der Kallen CJ, Schalkwijk CG, van den Berg LH, van Zwet EW, Mei H, Li Y, Lemire M, Hudson TJ; BIOS Consortium, Slagboom PE, Wijmenga C, Veldink JH, van Greevenbroek MM, van Duijn CM, Boomsma DI, Isaacs A, Jansen R, van Meurs JB, ‘t Hoen PA, Franke L, Heijmans BT. Nat Genet. 2017 Jan;49(1):131-138
4. Identification of context-dependent expression quantitative trait loci in whole blood. Zhernakova DV, Deelen P, Vermaat M, van Iterson M, van Galen M, Arindrarto W, van ‘t Hof P, Mei H, van Dijk F, Westra HJ, Bonder MJ, van Rooij J, Verkerk M, Jhamai PM, Moed M, Kielbasa SM, Bot J, Nooren I, Pool R, van Dongen J, Hottenga JJ, Stehouwer CD, van der Kallen CJ, Schalkwijk CG, Zhernakova A, Li Y, Tigchelaar EF, de Klein N, Beekman M, Deelen J, van Heemst D, van den Berg LH, Hofman A, Uitterlinden AG, van Greevenbroek MM, Veldink JH, Boomsma DI, van Duijn CM, Wijmenga C, Slagboom PE, Swertz MA, Isaacs A, van Meurs JB, Jansen R, Heijmans BT, ‘t Hoen PA, Franke L. Nat Genet. 2017 Jan;49(1):139-145. doi: 10.1038/ng.3737
5. Gene expression analysis identifies global gene dosage sensitivity in cancer. FehrmannRS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, te Meerman GJ, Wijmenga C, van Vugt MA, Franke L. Nat Genet. 2015 Feb;47(2):115-25.

December 15^th at 16:00
Hybrid event
Medisiina D, Säätiö-Sali / Zoom

Kaisu Rantakokko-Jalava
Uuden I:n määritelmä

Asko Järvinen, HUS
Mikä on iso annos mikrobilääkettä?

Esa Rintala, TYKS
Muiden infektiotautien epidemiologia COVID-19 –pandemian aikana

Zoom-linkki:
https://utu.zoom.us/j/67597804008

Luentoja (8 h) anotaan hyväksyttäväksi täydennyskoulutukseksi erikoislääkäri- ja erikoishammaslääkärikoulutukseen kaikille erikoisaloille ja tohtorin tutkinnon jatkokoulutukseen.

December 14th at 09:30
Hybrid event
Main Building, Säästöpankki lecture hall, and online
Flyer

Coffee and snack is served at 09:15 at the event venue.

Yagut Allahverdiyeva-Rinne, University of Turku
Introductory words

Eva-Mari Aro, University of Turku
Photosynthesis at the forefront of sustainability

Miikka Frantti, Solar Finland Group
Photovoltaic business in Finland, and R&D cooperation with higher education institutions

Kati Miettunen, University of Turku
Sustainable solar energy

Samuli Ranta, Turku University of Applied Sciences
Photovoltaic as part of the Nordic energy system

Jan-Henrik Smått, Åbo Akademi University
Research on emerging solar cells at Åbo Akademi University

The universities in Turku, in close collaboration with Turku Science Park, have launched a joint Aboa Tech Talks webinar series this autumn focusing on emerging technologies and sustainable development. Aboa Tech Talks aims to highlight advanced and innovative technological research and education carried in the universities that can offer sustainable solutions to the complex global challenges of our time.

The topic of the second Aboa Tech Talks is solar driven technologies and how researchers aim to address the major global sustainability challenges of our modern society. Solar powered technologies harness energy from sunlight, which is a main source of sustainable energy, and transform it into useable form in our daily lives. The goal of these technologies is to develop novel harvesting solutions for solar energy with higher conversion efficiencies. Aboa Tech Talks will stimulate a cooperation between the Universities, facilitate interaction with industry, and promote multidisciplinary education as an enabler of clean solar technology development in the Turku region.

Participants outside UTU, ÅAU, TUAS and Novia are invited to attend the event virtually.
The link to Flinga board to ask questions, and the link to join the virtual event will be sent to all registered participants one day before the event.

Register latest December 12^th
https://link.webropolsurveys.com/S/F5C6AE3A9A30DF2B

.

December 10^th at 13:00
Virtual event
Autumn 2021 program

Adj. Prof. Petra Sipilä
Runx transcription factors are necessary for maintenance of propler differentiation of epididymal epithelial cells

Sarah El Kharraz, Univeristy of Leuven, Belgium
Androgen receptor dimerization: frim crystals to nouse models

Bimonthly IPP seminar series covers the diversity of biomedical/medical research performed in Integrative Physiology and Pharmacology research unit plus interesting talks by visitors from national and international research collaboration networks.

Details to join the Zoom are available on the same week Monday in BioCity Announcements

October 28th at 09:00
on-site event
BioCity Presidentti auditorium

Alexander Mildner, Max-Delbrück Center for Molecular Medicine, Berlin, Germany
title tba

You are warmly welcome to the seminar of Alexander Mildner from Max-Delbrück Center for Molecular Medicine, Berlin, Germany. Alexander Mildner has applied for an InFLAMES Associate Professorship position and is a top candidate for the position. He will visit Turku from 27 to 29 October. Coffee/tea and sandwich is served before the start of the seminar.

If you would like to meet and talk with him in person, please email kaisa.hakkila@utu.fi.

October 12^th at 15:15
Hybrid event
Medisiina D  lecture hall Lauren 1 / Zoom

Prof. Simon L. Goodman, Science and Technology Program Manager, the Antibody Society, Germany
Integrins as drug targets

Professor Goodman will be holding his lecture about the topic of integrins as drug targets on-site in the Medisiina D lecture hall Lauren 1. If you wish to come on-site please  register latest Sunday October 10th
https://link.webropol.com/s/VP-Simon-Goodman

You can also follow the talk online via Zoom, where no registration is required:
https://utu.zoom.us/j/61710469294

Welcome everyone!

Simon L. Goodman is Science and Technology Program Manager for the Antibody Society. He gained his D.Phil in membrane biochemistry from the University of Sussex. His start-up biotechnology company works on antibody validation.  He spent many years at Merck inventing and developing peptide and antibody therapeutics targeting cell adhesion through phase 3 clinical trials in oncology. Prior to Merck, he did post-doctoral work at Max-Planck Society on cellular receptors for laminin, with Klaus von der Mark at Martinsried, Munich and Erlangen, and phenotypic antibody screens with Walter Birchmeier at MPI Tübingen. His work includes the first high resolution X-ray structures of integrins, in collaboration with Dr. Amin Arnaout (Harvard Medical School).  His career in academia and industry has resulted in over 100 peer-reviewed publications, reviews and in many patents.

October 12^th at 15:15
Hybrid event
Medisiina D  lecture hall Lauren 1 / Zoom

Prof. Simon L. Goodman, Science and Technology Program Manager, the Antibody Society, Germany
Integrins as drug targets

Professor Goodman will be holding his lecture about the topic of integrins as drug targets on-site in the Medisiina D lecture hall Lauren 1. If you wish to come on-site please  register latest Sunday October 10th
https://link.webropol.com/s/VP-Simon-Goodman

You can also follow the talk online via Zoom, where no registration is required:
https://utu.zoom.us/j/61710469294

Welcome everyone!

Simon L. Goodman is Science and Technology Program Manager for the Antibody Society. He gained his D.Phil in membrane biochemistry from the University of Sussex. His start-up biotechnology company works on antibody validation.  He spent many years at Merck inventing and developing peptide and antibody therapeutics targeting cell adhesion through phase 3 clinical trials in oncology. Prior to Merck, he did post-doctoral work at Max-Planck Society on cellular receptors for laminin, with Klaus von der Mark at Martinsried, Munich and Erlangen, and phenotypic antibody screens with Walter Birchmeier at MPI Tübingen. His work includes the first high resolution X-ray structures of integrins, in collaboration with Dr. Amin Arnaout (Harvard Medical School).  His career in academia and industry has resulted in over 100 peer-reviewed publications, reviews and in many patents.

October 11th at 11:15
Hybrid event
Medisiina D lecture hall Lauren 1 / Zoom

Prof. Simon L. Goodman, Science and Technology Program Manager, the Antibody Society, Germany
Drug discovery and how things are done in pharma

Professor Goodman will be holding his introductory lecture on-site in the Medisiina D Lecture Hall Lauren 1. If you wish to come on-site please register latest Sunday October 10^th
https://link.webropol.com/s/VP-Simon-Goodman

You can also follow the talk online via Zoom, where no registration is required:
https://utu.zoom.us/j/66366373791

Welcome everyone!

Simon L. Goodman is Science and Technology Program Manager for the Antibody Society. He gained his D.Phil in membrane biochemistry from the University of Sussex. His start-up biotechnology company works on antibody validation.  He spent many years at Merck inventing and developing peptide and antibody therapeutics targeting cell adhesion through phase 3 clinical trials in oncology. Prior to Merck, he did post-doctoral work at Max-Planck Society on cellular receptors for laminin, with Klaus von der Mark at Martinsried, Munich and Erlangen, and phenotypic antibody screens with Walter Birchmeier at MPI Tübingen. His work includes the first high resolution X-ray structures of integrins, in collaboration with Dr. Amin Arnaout (Harvard Medical School).  His career in academia and industry has resulted in over 100 peer-reviewed publications, reviews and in many patents.

Special seminar, program will be announced later

Zoom details 
https://utu.zoom.us/j/67279196618
Meeting ID: 672 7919 6618
Passcode: 878028

May 19^th at 13:00
Virtual event

We will be hosting Prof. Vincenzo Cerullo, Group leader of ImmunoViroTherapy Lab, University of Helsinki, for the talk. The duration of the talk is 30 mins followed by 15 mins of discussion and interaction with the speaker.
Title of the talk: “Dressing up viruses to fool cancer”

Flyer pdf

You can register here: http://bit.ly/cerullo. This link is active until 18th May 23:59.

Brief Bio about the speaker: Prof. Vincenzo Cerullo, Vince is professor of Biological Drug Development, Faculty of Pharmacy, Head of Drug Research Program, HiLIFE fellow, Translational Immunology Programme, University of Helsinki. Vince got his PhD at Centre for genetic Engineering (CENIGE) at University of Naples, Federico II in 2004, then he moved to Houston Texas (USA) for a postdoc at Baylor College of Medicine. In 2009 he moved to University of Helsinki where he worked as senior researcher until 2012 when he was awarded the tenure-track professorship and started the ImmunoViroTherapy Lab.  In these years IVTLab has raised more than 7 million Euros for research, including the prestigious ERC Consolidator Grant, ERC-PoC, HiLIFE fellow and Jane and Aatos Erkko Foundation grant. The group has produced tens of scientific papers and patents and has co-founded a multimillion spin-off company together with the University of Helsinki (VALO therapeutics). Vince has been awarded the Outstading Young Investigator award in 2014 by the European Society of Gene and cell Therapy and the Excellence in Research award by the American Society of Gene and Cell Therapy in 2015; he has been recently ranked number one globally, third in Europe and number one in the nordic in his own experitiese (oncolytic virotherapy) by expertscape.

One of Vince’s passion is science dissemination, this is why has been involved from the beginning in organizing the Science track in Slush, he has pitched himself on the Slush stage in 2015, 2016 and on the Slush Y Science stage in 2017 (www.slush.org). Among other things, he has also presented a TEDx talk on the importance of creativity in science (https://youtu.be/1btbElPnREI)

More details about research can be found here: https://www2.helsinki.fi/en/researchgroups/immunovirotherapy-lab/research

May 19^th at 13:00
Virtual event

We will be hosting Prof. Vincenzo Cerullo, Group leader of ImmunoViroTherapy Lab, University of Helsinki, for the talk. The duration of the talk is 30 mins followed by 15 mins of discussion and interaction with the speaker.
Title of the talk: “Dressing up viruses to fool cancer”

Flyer pdf

You can register here: http://bit.ly/cerullo. This link is active until 18th May 23:59.

Brief Bio about the speaker: Prof. Vincenzo Cerullo, Vince is professor of Biological Drug Development, Faculty of Pharmacy, Head of Drug Research Program, HiLIFE fellow, Translational Immunology Programme, University of Helsinki. Vince got his PhD at Centre for genetic Engineering (CENIGE) at University of Naples, Federico II in 2004, then he moved to Houston Texas (USA) for a postdoc at Baylor College of Medicine. In 2009 he moved to University of Helsinki where he worked as senior researcher until 2012 when he was awarded the tenure-track professorship and started the ImmunoViroTherapy Lab.  In these years IVTLab has raised more than 7 million Euros for research, including the prestigious ERC Consolidator Grant, ERC-PoC, HiLIFE fellow and Jane and Aatos Erkko Foundation grant. The group has produced tens of scientific papers and patents and has co-founded a multimillion spin-off company together with the University of Helsinki (VALO therapeutics). Vince has been awarded the Outstading Young Investigator award in 2014 by the European Society of Gene and cell Therapy and the Excellence in Research award by the American Society of Gene and Cell Therapy in 2015; he has been recently ranked number one globally, third in Europe and number one in the nordic in his own experitiese (oncolytic virotherapy) by expertscape.

One of Vince’s passion is science dissemination, this is why has been involved from the beginning in organizing the Science track in Slush, he has pitched himself on the Slush stage in 2015, 2016 and on the Slush Y Science stage in 2017 (www.slush.org). Among other things, he has also presented a TEDx talk on the importance of creativity in science (https://youtu.be/1btbElPnREI)

More details about research can be found here: https://www2.helsinki.fi/en/researchgroups/immunovirotherapy-lab/research

Janne Koskinen, ArcDia International Oy
Company perspective on R&D in clinical microbiology and virology

Organized in Zoom
https://utu.zoom.us/j/7562392825

2 ECTS
KAB24007 (UTU)
TK00BS28-3003 (ÅAU)

course description
detailed program

Registration latest April 13th via Nettiopsu (UTU) or Peppi (ÅAU)

If you are from other organization but would ilke to register, please contact the responsible teachers.

The course deals with basic concepts of sustainability, bioeconomy and circular economy. It gives an overview of current and potential bioeconomy in Finland, starting from biomass resources and advanced conversion technologies to national and EU strategies. Lectures are given by top experts from different fields in industry and academia and the course includes a virtual excursion to the Smart Chemistry Park, which is South Western Finland’s technology innovation park largely devoted to bioeconomy and cleantech.

Academic lecturers
Eva-Mari Aro, University of Turku
Markku Kulmala, Univesity of Helsinki
Henrik Grénman, Åbo Akademi University
Yagut Allahverdiyeva, University of Turku
Chunlin Xu, Åbo Akademi University
Pauli Kallio, University of Turku
Tekla Tammelin, FinnCERES Flagship
Mikko Pohjola, University of UTU

Industry lecturers
Maija Pohjakallio, Sulapac Ltd.
Lari Vähäsalo, CH Bioforce
Antoine Mialon, MetGen
Aino-Maija Lakaniemi, Neste Oy
Blanka Toukoniitty, Neste Oy
Elina Peltomaa, Algonomy
Linda Fröberg-Niemi, Smart Chemistry Park

The students are expected to keep a learning diary throughout the course and at the end of the course each student is assigned one of the topics to plunge into and to write a final report. The in-depth essay should describe the Finnish as well as global current situation, reflect on the future and include literature search.

The course lasts three full days and requires full attendance but in case of colliding events students need to be in contact with the responsible teachers in advance. More detailed program is available in SmartBio web pages www.smartbio.fi as well as in Moodle. The course is intended for advanced Master students as well as for PhD students.

Responsible teachers 
Prof. Yagut Allahverdiyeva (allahve@utu.fi)
Prof. Henrik Grénman (henrik.grenman@abo.fi)

2 ECTS
KAB24007 (UTU)
TK00BS28-3003 (ÅAU)

course description
detailed program

Registration latest April 13th via Nettiopsu (UTU) or Peppi (ÅAU)

If you are from other organization but would ilke to register, please contact the responsible teachers.

The course deals with basic concepts of sustainability, bioeconomy and circular economy. It gives an overview of current and potential bioeconomy in Finland, starting from biomass resources and advanced conversion technologies to national and EU strategies. Lectures are given by top experts from different fields in industry and academia and the course includes a virtual excursion to the Smart Chemistry Park, which is South Western Finland’s technology innovation park largely devoted to bioeconomy and cleantech.

Academic lecturers
Eva-Mari Aro, University of Turku
Markku Kulmala, Univesity of Helsinki
Henrik Grénman, Åbo Akademi University
Yagut Allahverdiyeva, University of Turku
Chunlin Xu, Åbo Akademi University
Pauli Kallio, University of Turku
Tekla Tammelin, FinnCERES Flagship
Mikko Pohjola, University of UTU

Industry lecturers
Maija Pohjakallio, Sulapac Ltd.
Lari Vähäsalo, CH Bioforce
Antoine Mialon, MetGen
Aino-Maija Lakaniemi, Neste Oy
Blanka Toukoniitty, Neste Oy
Elina Peltomaa, Algonomy
Linda Fröberg-Niemi, Smart Chemistry Park

The students are expected to keep a learning diary throughout the course and at the end of the course each student is assigned one of the topics to plunge into and to write a final report. The in-depth essay should describe the Finnish as well as global current situation, reflect on the future and include literature search.

The course lasts three full days and requires full attendance but in case of colliding events students need to be in contact with the responsible teachers in advance. More detailed program is available in SmartBio web pages www.smartbio.fi as well as in Moodle. The course is intended for advanced Master students as well as for PhD students.

Responsible teachers 
Prof. Yagut Allahverdiyeva (allahve@utu.fi)
Prof. Henrik Grénman (henrik.grenman@abo.fi)

Alesia Levanova, University of Helsinki
Purification and analysis of small RNA molecules using asymmetrical flow field-flow fractionation (AF4)

Organized in Zoom
https://utu.zoom.us/j/7562392825

Karolina Louvanto, Methylation markers in cervical cancer screening
Akira Takeda, Stromal and immune cell interactions in health and disease

Zoom details
https://utu.zoom.us/j/67279196618
Meeting ID: 672 7919 6618
Passcode: 878028

Tom Wiklund, Åbo Akademi University
Bacteriophages as biocontrol agents for cold water disease in farmed rainbow trout

Organized in Zoom
https://utu.zoom.us/j/7562392825

Turku Cancer Research Society and FICAN West welcome you to join a seminar afternoon “State-of-the-art methodologies in cancer research”. It will be an online meeting via Zoom:

https://utu.zoom.us/j/61464679658
ID: 614 6467 9658
Passcode: 365521

Programme

Session I:
13.00-13.25 Riikka Lund “Supporting high-level research with state-of-the-art tools for genomics”
13.25-13.50 Hongbo Zhang “Advanced Materials and Nanotechnology on Cancer Treatment” (changed)
13.50-14.15 Mari Suominen “Learning curve for using CD34 engrafted humanized mice”
14.15-14.40 Tove Grönroos “New applications in animal PET/CT imaging”

Break

Session II:
15.00-15.25 Christoffer Löf “The CRISPR toolkit in cancer research” (changed)
15.25-15.50 Pekka Ruusuvuori “Artificial intelligence for cancer diagnostics and grading” (changed)
15.50-16.15 Sofia Khan “Where lies the power of genome-wide association studies (GWAS)”
16.15-16.30 Discussion and closing

Turku Doctoral Programme in Molecular Medicine (TuDMM) and the Finnish Euro-BioImaging Node is happy to announce a course “Basic Concepts of Bioimage Analysis” taking place in Turku BioCity between 12th-14th of June. The course will start at 12:00 on the 12th of June and complete at 17:00 on the 14th of June.

The course is aimed at graduate students, post-doctoral researchers, and everyone else who has background in imaging and microscopy and wish to gain additional insights into image analysis.

The 3-day course aims to cover the basics of image analysis and ethics involved in image analysis, fundamental concepts including convolution, segmentation, and many others with a hands-on practical component using ImageJ image analysis software working on participants’ own image analysis problems.

The maximum number of participants is 25 with participants selected based on their imaging background and suitability for the course.

More information here

Please register here: https://link.webropolsurveys.com/S/725C6B9DC91D0404

We are looking forward to your participation in this course.

Turku Doctoral Programme in Molecular Medicine (TuDMM) and the Finnish Euro-BioImaging Node is happy to announce a course “Basic Concepts of Bioimage Analysis” taking place in Turku BioCity between 12th-14th of June. The course will start at 12:00 on the 12th of June and complete at 17:00 on the 14th of June.

The course is aimed at graduate students, post-doctoral researchers, and everyone else who has background in imaging and microscopy and wish to gain additional insights into image analysis.

The 3-day course aims to cover the basics of image analysis and ethics involved in image analysis, fundamental concepts including convolution, segmentation, and many others with a hands-on practical component using ImageJ image analysis software working on participants’ own image analysis problems.

The maximum number of participants is 25 with participants selected based on their imaging background and suitability for the course.

More information here

Please register here: https://link.webropolsurveys.com/S/725C6B9DC91D0404

We are looking forward to your participation in this course.

Kati Kemppainen (Sahlgren lab): Introduction to the Cell Fate Lab

Maria Georgiadou (Orion Pharma): Making the transition – how to become a scientist in the industry

Kati Kemppainen (Sahlgren lab): Introduction to the Cell Fate Lab

Maria Georgiadou (Orion Pharma): Making the transition – how to become a scientist in the industry

Spring Seminar Event – Prostate Cancer:

13-13.05 Maria Sundvall – Opening and introduction

13.05-13.25 Peter Boström “Treatment of localized prostate cancer”

13.25-13.45 Heikki Minn “Molecular imaging in prostate cancer”

13.45-14.30 Steven Bova “Evolution of lethal prostate cancer at primary and metastatic sites: Can we identify what is important?”

14.30-15.00 Coffee break & Sponsors talk

15.00-15.20 Laura Elo ”How machine learning can improve treatment of prostate cancer”

15.20-15.40 Riikka Oksala “Androgen signaling axis as drug target in castration-resistant prostate cancer”

15.40-16.00 Kirsi Ketola “Cellular plasticity in lethal neuroendocrine prostate cancer”

16.00-16.30 Presentations by winners of grants

16.30 Sparkling wine and snacks

Register by email no later than 3.5.2019: contact-tcrs@lists.utu.fi

Printable programme here

Spring Seminar Event – Prostate Cancer:

13-13.05 Maria Sundvall – Opening and introduction

13.05-13.25 Peter Boström “Treatment of localized prostate cancer”

13.25-13.45 Heikki Minn “Molecular imaging in prostate cancer”

13.45-14.30 Steven Bova “Evolution of lethal prostate cancer at primary and metastatic sites: Can we identify what is important?”

14.30-15.00 Coffee break & Sponsors talk

15.00-15.20 Laura Elo ”How machine learning can improve treatment of prostate cancer”

15.20-15.40 Riikka Oksala “Androgen signaling axis as drug target in castration-resistant prostate cancer”

15.40-16.00 Kirsi Ketola “Cellular plasticity in lethal neuroendocrine prostate cancer”

16.00-16.30 Presentations by winners of grants

16.30 Sparkling wine and snacks

Register by email no later than 3.5.2019: contact-tcrs@lists.utu.fi

Printable programme here

Hussein Al-Akhrass SorLA – a novel oncogenic regulator of HER2-amplified breast cancer

Minna Piipponen Long non-coding RNAs in cutaneous squamous cell carcinoma

Hussein Al-Akhrass SorLA – a novel oncogenic regulator of HER2-amplified breast cancer

Minna Piipponen Long non-coding RNAs in cutaneous squamous cell carcinoma

Maija Hollmen Converting cold tumors hot -A macrophage targeted approach

Sami Ventelä New tools to diagnose and treat head and neck squamous cell carcinoma (HNSCC)

Maija Hollmen Converting cold tumors hot -A macrophage targeted approach

Sami Ventelä New tools to diagnose and treat head and neck squamous cell carcinoma (HNSCC)

Valeriy Paramonov Profiling Notch signalling in digestive endocrine cancers

Maria Gardberg Exploring novel fusion genes in glioblastoma

Valeriy Paramonov Profiling Notch signalling in digestive endocrine cancers

Maria Gardberg Exploring novel fusion genes in glioblastoma

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM
TRANSLATING MOLECULES TO TREATMENTS II

9.00-9.10 Opening words by Professor Lea Sistonen

9.10-10.00 Thomas Kirkegaard Jensen Orphazyme – From Biology to Bedside

Thomas Kirkegaard Jensen is a PhD and Chief Scientific Officer of Orphazyme ApS in Denmark. Orphazyme develops new therapies for patients suffering from protein-misfolding diseases with no or limited treatment options available. Orphazyme was founded on the initial discovery made by Thomas during his doctoral studies in the laboratory of Professor Marja Jäättelä at the Danish Cancer Society, in which they found that the molecular chaperone, heat shock protein 70, reverts the pathology associated with lysosomal storage diseases. Based on this finding the company develops of new treatments for lysosomal storage diseases.

10.00-10.20 Coffee break

10.20-11.10 Rajwinder Lehal From Cell to Cellestia – Transition of a PhD Project Into a Drug Development Company

Rajwinder Lehal is a PhD and co-founder of Cellestia Biotech AG in Switzerland. The aim of Cellestia Biotech is to develop innovative therapeutics for cancer treatment. At Cellestia Biotech, he is Chief Scientific Officer and serves on the Board of Directors. Cellestia Biotech has developed a targeted therapy designed to treat cancers resulting from a mutation of the Notch gene. Molecule CB-103, discovered by Rajwinder Lehal during his doctoral studies in Professor Freddy Radtke’s laboratory at EPFL, cuts off Notch signals leading to cell death of cancer cells.

11.10-12.00 Mads Daugaard Leveraging Placental Malaria Tropism for Cancer Therapeutic and Diagnostic Applications

Mads Daugaard is an Assistant Professor and group leader at Vancouver Prostate Centre at University of British Columbia and the Co-founder and Chairman of the Board of Directors of three biotech companies; VAR2 Pharmaceuticals, OncoMal and VarCT Diagnostics in Canada. Mads is a molecular biologist specialized in tumour-associated stress signaling pathways and tumour targeting systems. His research focuses on alternative polyadenylation of mRNAs, chromatin context-dependent DNA repair, development of resistance to chemotherapy, and immune evasion mechanisms in cancer. Another aspect of Mads’ research relates to discovery and development of novel tumour targeting systems based on parasite-derived recombinant proteins relevant for therapeutic and diagnostic applications in cancer.

12.30-14.00 Round table lunch with speakers
Round table discussions including lunch for students and postdocs in groups of 10 students/postdocs per speaker. The 30 first to register will be admitted.

Register before Friday January 11th  at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Annika Meinander, e-mail: annika.meinander@abo.fi

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM
TRANSLATING MOLECULES TO TREATMENTS II

9.00-9.10 Opening words by Professor Lea Sistonen

9.10-10.00 Thomas Kirkegaard Jensen Orphazyme – From Biology to Bedside

Thomas Kirkegaard Jensen is a PhD and Chief Scientific Officer of Orphazyme ApS in Denmark. Orphazyme develops new therapies for patients suffering from protein-misfolding diseases with no or limited treatment options available. Orphazyme was founded on the initial discovery made by Thomas during his doctoral studies in the laboratory of Professor Marja Jäättelä at the Danish Cancer Society, in which they found that the molecular chaperone, heat shock protein 70, reverts the pathology associated with lysosomal storage diseases. Based on this finding the company develops of new treatments for lysosomal storage diseases.

10.00-10.20 Coffee break

10.20-11.10 Rajwinder Lehal From Cell to Cellestia – Transition of a PhD Project Into a Drug Development Company

Rajwinder Lehal is a PhD and co-founder of Cellestia Biotech AG in Switzerland. The aim of Cellestia Biotech is to develop innovative therapeutics for cancer treatment. At Cellestia Biotech, he is Chief Scientific Officer and serves on the Board of Directors. Cellestia Biotech has developed a targeted therapy designed to treat cancers resulting from a mutation of the Notch gene. Molecule CB-103, discovered by Rajwinder Lehal during his doctoral studies in Professor Freddy Radtke’s laboratory at EPFL, cuts off Notch signals leading to cell death of cancer cells.

11.10-12.00 Mads Daugaard Leveraging Placental Malaria Tropism for Cancer Therapeutic and Diagnostic Applications

Mads Daugaard is an Assistant Professor and group leader at Vancouver Prostate Centre at University of British Columbia and the Co-founder and Chairman of the Board of Directors of three biotech companies; VAR2 Pharmaceuticals, OncoMal and VarCT Diagnostics in Canada. Mads is a molecular biologist specialized in tumour-associated stress signaling pathways and tumour targeting systems. His research focuses on alternative polyadenylation of mRNAs, chromatin context-dependent DNA repair, development of resistance to chemotherapy, and immune evasion mechanisms in cancer. Another aspect of Mads’ research relates to discovery and development of novel tumour targeting systems based on parasite-derived recombinant proteins relevant for therapeutic and diagnostic applications in cancer.

12.30-14.00 Round table lunch with speakers
Round table discussions including lunch for students and postdocs in groups of 10 students/postdocs per speaker. The 30 first to register will be admitted.

Register before Friday January 11th  at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Annika Meinander, e-mail: annika.meinander@abo.fi

Professor James M Musser, Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas

The many secret lives of group A streptococcus, a human flesh-eating pathogen

Professor James M Musser, Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas

The many secret lives of group A streptococcus, a human flesh-eating pathogen

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM

TRANSLATING MOLECULES TO TREATMENTS I

13.00-13.10 Opening words by Associate Professor Diana Toivola

13.10-14.00 M. Bishr Omary Molecular Pathogenesis of Porphyria and Therapeutic Approaches Using Zebrafish Models

M. Bishr Omary is Professor of Molecular & Integrative Physiology, the H Marvin Pollard Professor of Gastroenterology, Professor of Internal Medicine, and Special Advisor on Research to the Dean at University of Michigan in Ann Arbor, USA. He is also guest professor in Drug Development and Diagnostics at Åbo Akademi University in Turku. Bishr is a world leader in the area of intermediate filamentsand their associated diseases, with special focus on the regulation and function of keratins and lamins in digestive organs. Another active area of research in his laboratory involves studying the mechanism of porphyrin mediated cell damage in the context of the genetic porphyria disorders. He currently utilizes high throughput drug screening approaches to identify compounds with potential therapeutic benefits for intermediate filament associated diseases and for porphyrias.

https://medicine.umich.edu/dept/molecular-integrative-physiology/bishr-omary-md-phd

14:00-14.50 Caroline Heckman Personalizing Patient Care to Overcome Drug Resistance in Hematological Malignancies

Caroline Heckman is a Group leader and Principal Investigator at the Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Sciences, University of Helsinki in Finland. Caroline’s research is focused on understanding the mechanisms driving disease progression and drug resistance in hematological malignancies. She also applies technologies for better translation of basic research results towards clinical implementation.

https://www.fimm.fi/en/research/groups/heckman

14.50-15.10 Coffee break

15.10-16.00 “The ABCs of a postdoc in the US” with M. Bishr Omary

This interactive session is open to all interested and will cover tips and advice on doing a postdoc in general and especially related to being a postdoc in US.

Register before Friday January 11th at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Diana Toivola, e-mail: diana.toivola@abo.fi

DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM

TRANSLATING MOLECULES TO TREATMENTS I

13.00-13.10 Opening words by Associate Professor Diana Toivola

13.10-14.00 M. Bishr Omary Molecular Pathogenesis of Porphyria and Therapeutic Approaches Using Zebrafish Models

M. Bishr Omary is Professor of Molecular & Integrative Physiology, the H Marvin Pollard Professor of Gastroenterology, Professor of Internal Medicine, and Special Advisor on Research to the Dean at University of Michigan in Ann Arbor, USA. He is also guest professor in Drug Development and Diagnostics at Åbo Akademi University in Turku. Bishr is a world leader in the area of intermediate filamentsand their associated diseases, with special focus on the regulation and function of keratins and lamins in digestive organs. Another active area of research in his laboratory involves studying the mechanism of porphyrin mediated cell damage in the context of the genetic porphyria disorders. He currently utilizes high throughput drug screening approaches to identify compounds with potential therapeutic benefits for intermediate filament associated diseases and for porphyrias.

https://medicine.umich.edu/dept/molecular-integrative-physiology/bishr-omary-md-phd

14:00-14.50 Caroline Heckman Personalizing Patient Care to Overcome Drug Resistance in Hematological Malignancies

Caroline Heckman is a Group leader and Principal Investigator at the Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Sciences, University of Helsinki in Finland. Caroline’s research is focused on understanding the mechanisms driving disease progression and drug resistance in hematological malignancies. She also applies technologies for better translation of basic research results towards clinical implementation.

https://www.fimm.fi/en/research/groups/heckman

14.50-15.10 Coffee break

15.10-16.00 “The ABCs of a postdoc in the US” with M. Bishr Omary

This interactive session is open to all interested and will cover tips and advice on doing a postdoc in general and especially related to being a postdoc in US.

Register before Friday January 11th at https://survey.abo.fi/lomakkeet/10837/lomake.html

For more information, contact Diana Toivola, e-mail: diana.toivola@abo.fi

Special guest seminar

Johan Hartman, Karolinska Institute, Sweden
Precision pathology – from molecule to drug development

Dr Hartman is a principal investigator at Karolinska Institutet, Dept of Oncology and Pathology. His research focuses on breast cancer diagnosis with emphasis on tumor heterogeneity and ex vivo drug profiling. He has co-published several papers on the role of heterogeneity and cancer stem cells for therapeutic resistance. His team also has interest in image analysis for histopathology. Proliferation is a central factor for breast tumorigenesis but also for subclassification of tumors. Hartmans team has worked many years to develop computer-assisted methods to classify breast cancers based on proliferation. Currently they are applying deep-learning algorithms to improve cancer diagnosis. Dr Hartman is a clinically active breast pathologist at Karolinska University Laboratory and head of the Swedish expert group in breast pathology (KVAST-bröstcancer).

Some selected papers:
Kim C, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018 May 3

Ullah I, et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph-nodes. J Clin Invest. 2018 Apr 2

Ma R, et al. Estrogen receptor β as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst. 2017 Mar 1

Rantalainen M, et al. Sci Rep. 2016 Nov 30.

Stålhammar G, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016 Apr 29

Special guest seminar

Johan Hartman, Karolinska Institute, Sweden
Precision pathology – from molecule to drug development

Dr Hartman is a principal investigator at Karolinska Institutet, Dept of Oncology and Pathology. His research focuses on breast cancer diagnosis with emphasis on tumor heterogeneity and ex vivo drug profiling. He has co-published several papers on the role of heterogeneity and cancer stem cells for therapeutic resistance. His team also has interest in image analysis for histopathology. Proliferation is a central factor for breast tumorigenesis but also for subclassification of tumors. Hartmans team has worked many years to develop computer-assisted methods to classify breast cancers based on proliferation. Currently they are applying deep-learning algorithms to improve cancer diagnosis. Dr Hartman is a clinically active breast pathologist at Karolinska University Laboratory and head of the Swedish expert group in breast pathology (KVAST-bröstcancer).

Some selected papers:
Kim C, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018 May 3

Ullah I, et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph-nodes. J Clin Invest. 2018 Apr 2

Ma R, et al. Estrogen receptor β as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst. 2017 Mar 1

Rantalainen M, et al. Sci Rep. 2016 Nov 30.

Stålhammar G, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016 Apr 29

Urpo Lamminmäki, University of Turku
Synthetic Antibodies – Affinity Tools for Unmet Needs

Host: Jukka Alinikula

Urpo Lamminmäki, University of Turku
Synthetic Antibodies – Affinity Tools for Unmet Needs

Host: Jukka Alinikula

Mikko Metsä-Ketelä, University of Turku
Development of C-nucleoside antibiotics for inhibition of bacterial RNA polymerases.

Host: Kirsi Gröndahl-Yli-Hannuksela.

Mikko Metsä-Ketelä, University of Turku
Development of C-nucleoside antibiotics for inhibition of bacterial RNA polymerases.

Host: Kirsi Gröndahl-Yli-Hannuksela.

Program:
14.45 Sparkling wine
15.15 Lauri Aaltonen, University of Helsinki – “Genome sequencing in intestinal cancer”
16.15 Johanna Hynninen, Turku University Hospital – “Ovarian Cancer – Clinical aspects and ongoing research projects”
16.50 PhD award –lecture
17.10 Snacks and drinks

Registrations by November 26 via email: contact-tcrs (at) lists.utu.fi
Please also indicate a possible special diet when registering.

Please renew your membership or become a member for 2018 by paying the 10 €  annual membership fee on the Society’s bank account before the seminar (FI7612093000051335,  Turun Syöpätutkijat Ry, please use your name as a refenrence).

Program:
14.45 Sparkling wine
15.15 Lauri Aaltonen, University of Helsinki – “Genome sequencing in intestinal cancer”
16.15 Johanna Hynninen, Turku University Hospital – “Ovarian Cancer – Clinical aspects and ongoing research projects”
16.50 PhD award –lecture
17.10 Snacks and drinks

Registrations by November 26 via email: contact-tcrs (at) lists.utu.fi
Please also indicate a possible special diet when registering.

Please renew your membership or become a member for 2018 by paying the 10 €  annual membership fee on the Society’s bank account before the seminar (FI7612093000051335,  Turun Syöpätutkijat Ry, please use your name as a refenrence).

Ilona Rissanen, University of Helsinki
Molecular architecture of hantaviruses: keys to infection and virus neutralization

Host: Sisko Tauriainen.

Ilona Rissanen, University of Helsinki
Molecular architecture of hantaviruses: keys to infection and virus neutralization

Host: Sisko Tauriainen.

Annukka Pietikäinen, University of Turku
Pathogenesis and diagnostics of Lyme borreliosis

Host: Jukka Hytönen.

Annukka Pietikäinen, University of Turku
Pathogenesis and diagnostics of Lyme borreliosis

Host: Jukka Hytönen.

Coffee/tea and snack available before the talks

The two speakers:

1. Guido Serini (University of Torino Medical School)

• Title of talk: “Mechanisms of β1 integrin activation and clustering in the control of endothelial cell adhesion and migration”. This will be unpublished data.
• If time allows, Prof Serini will also summarise some recent work on semaphorin, its co-receptor neuropilin 1 and new binding partners and the implications of these novel interactions in vascular morphogenesis and function.

In his earlier work, Prof Serini showed for the first time how endothelial class 3 semaphorins (SEMA3) signal through plexin receptors to inhibit integrins and allow vascular morphogenesis (Serini et al., Nature 2003). More recently, his research group rationally designed, generated and characterized a mutant, protease resistant, and easily purifiable superagonist SEMA3A protein isoform that represents a parenterally-deliverable drug that effectively normalizes the cancer vasculature (Gioelli et al., Sci. Transl. Med. 2018). His lab has also unveiled how vascular morphogenesis relies not only on integrin conformational activation, but also on dedicated signalling pathways that control the endocytosis and recycling of conformationally active integrins to adhesion sites in coordination with TGN-dependent polarized fibronectin secretion (Valdembri et al., PloS Biol. 2009; Sandri et al., Cell Res. 2012; Mana et al., Nat. Commun. 2016).

Prof. Serini will serve as Pranshu Sahgal’s PhD opponent on Friday 16^th November!

Selected publications (Guido Serini):

                Semaphorins and angiogenesis

• G. Serini*, V. Valdembri, S. Zanivan, G. Morterra, C. Burkhardt, F. Caccavari, L. Zammataro, L. Primo, L. Tamagnone, M. Logan, M. Tessier-Lavigne, M. Taniguchi, A.W. Püschel, and F. Bussolino*. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003, 424: 391-397. *Shared corresponding authorship.
• F. Maione, F. Molla, C. Meda, R. Latini, L. Zentilin, M. Giacca, G. Seano, G. Serini*, F. Bussolino*, and E. Giraudo*. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119: 3356-3372. *Shared senior authorship.
• N. Gioelli, F. Maione, C. Camillo, M. Ghitti, D. Valdembri, N. Morello, M. Darche, L. Zentilin, G. Cagnoni, Y. Qiu, M. Giacca, M. Giustetto, M. Paques, I. Cascone, G. Musco, L. Tamagnone, E. Giraudo, and G. Serini. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci. Transl. Med. 2018, 10: eaah4807.

                Active integrin traffic

• D. Valdembri, P.T. Caswell, K.I. Anderson, J.P. Schwarz, I. König, E. Astanina, F. Caccavari, J.C. Norman, M.J. Humphries, F. Bussolino, and G. Serini. Neuropilin−1/GIPC1 Signaling Regulates α5β1 Integrin Traffic and Function in Endothelial Cells. PLoS Biology 2009, 7:e1000025.
• C. Sandri, F. Caccavari, D. Valdembri, C. Camillo, S. Veltel, M. Santambrogio, L. Lanzetti, F. Bussolino, J. Ivaska, and G. Serini. The R-Ras/RIN2/Rab5 complex controls endothelial cell adhesion and morphogenesis via active integrin endocytosis and Rac signaling. Cell Res. 2012, 22:1479-1501.
• G. Mana, F. Clapero, E. Panieri, V. Panero, R. T. Böttcher, H.Y. Tseng, F. Saltarin, E. Astanina, K.I. Wolanska, M. R. Morgan, M.J. Humphries, M.M. Santoro, G. Serini*, and D. Valdembri*. PPFIA1 drives active α5β1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis. Nat. Commun. 2016, 7: 13546. *Shared senior and corresponding authorship.

2. Stephanie Miserey-Linkei (Institut Curie, PSL Research University)

• Title of talk: “Getting out the Golgi complex thanks to the RAB6 GTPase”

Dr Miserey-Linkei is a talented senior researcher in the group of Prof. Bruno Goud in Institut Curie. She investigates the mechanisms regulating cellular transport with a focus on unravelling the role of Rab GTPases, the Golgi network and microtubules in this important biological process.

Selected publications (Stephanie Miserey-Linkei):

• Miserey-Lenkei S, Bousquet H, Pylypenko O, Bardin S, Dimitrov A, Bressanelli, G, Bonifay R, Fraisier V, Guillou C, Bougeret C, Houdusse A, Echard A, Goud B. Coupling fission and exit of RAB6 vesicles at Golgi hotspots through kinesin-myosin interactions. Nat Commun. 2017, 8(1):1254.
• Patwardhan A, Bardin S, Miserey-Lenkei S, Larue L, Goud B, Raposo G, Delevoye C. Routing of the RAB6 secretory pathway towards the lysosome related organelle of melanocytes. Nat Commun. 2017, 8:15835.
• Miserey-Lenkei S, Colombo MI. Small RAB GTPases Regulate Multiple Steps of Mitosis. Front Cell Dev Biol. 2016, 4:2. Review.
• Delevoye C, Miserey-Lenkei S, Montagnac G, Gilles-Marsens F, Paul-Gilloteaux P, Giordano F, Waharte F, Marks MS, Goud B, Raposo G. Recycling endosome tubule morphogenesis from sorting endosomes requires the kinesin motor KIF13A. Cell Rep. 2014, 6(3):445-54.
• Al Awabdh S, Miserey-Lenkei S, Bouceba T, Masson J, Kano F, Marinach-Patrice C, Hamon M, Emerit MB, Darmon M. A new vesicular scaffolding complex mediates the G-protein-coupled 5-HT1A receptor targeting to neuronal dendrites. J Neurosci. 2012, 32(41):14227-41.
• Miserey-Lenkei S, Waharte F, Boulet A, Cuif MH, Tenza D, El Marjou A, Raposo G, Salamero J, Héliot L, Goud B, Monier S. Rab6-interacting protein 1 links Rab6 and Rab11 function. Traffic. 2007, 8(10):1385-403.
• Miserey-Lenkei S, Couëdel-Courteille A, Del Nery E, Bardin S, Piel M, Racine V, Sibarita JB, Perez F, Bornens M, Goud B. A role for the Rab6A’ GTPase in the inactivation of the Mad2-spindle checkpoint. EMBO J. 2006, 25(2):278-89.

Coffee/tea and snack available before the talks

The two speakers:

1. Guido Serini (University of Torino Medical School)

• Title of talk: “Mechanisms of β1 integrin activation and clustering in the control of endothelial cell adhesion and migration”. This will be unpublished data.
• If time allows, Prof Serini will also summarise some recent work on semaphorin, its co-receptor neuropilin 1 and new binding partners and the implications of these novel interactions in vascular morphogenesis and function.

In his earlier work, Prof Serini showed for the first time how endothelial class 3 semaphorins (SEMA3) signal through plexin receptors to inhibit integrins and allow vascular morphogenesis (Serini et al., Nature 2003). More recently, his research group rationally designed, generated and characterized a mutant, protease resistant, and easily purifiable superagonist SEMA3A protein isoform that represents a parenterally-deliverable drug that effectively normalizes the cancer vasculature (Gioelli et al., Sci. Transl. Med. 2018). His lab has also unveiled how vascular morphogenesis relies not only on integrin conformational activation, but also on dedicated signalling pathways that control the endocytosis and recycling of conformationally active integrins to adhesion sites in coordination with TGN-dependent polarized fibronectin secretion (Valdembri et al., PloS Biol. 2009; Sandri et al., Cell Res. 2012; Mana et al., Nat. Commun. 2016).

Prof. Serini will serve as Pranshu Sahgal’s PhD opponent on Friday 16^th November!

Selected publications (Guido Serini):

                Semaphorins and angiogenesis

• G. Serini*, V. Valdembri, S. Zanivan, G. Morterra, C. Burkhardt, F. Caccavari, L. Zammataro, L. Primo, L. Tamagnone, M. Logan, M. Tessier-Lavigne, M. Taniguchi, A.W. Püschel, and F. Bussolino*. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003, 424: 391-397. *Shared corresponding authorship.
• F. Maione, F. Molla, C. Meda, R. Latini, L. Zentilin, M. Giacca, G. Seano, G. Serini*, F. Bussolino*, and E. Giraudo*. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119: 3356-3372. *Shared senior authorship.
• N. Gioelli, F. Maione, C. Camillo, M. Ghitti, D. Valdembri, N. Morello, M. Darche, L. Zentilin, G. Cagnoni, Y. Qiu, M. Giacca, M. Giustetto, M. Paques, I. Cascone, G. Musco, L. Tamagnone, E. Giraudo, and G. Serini. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci. Transl. Med. 2018, 10: eaah4807.

                Active integrin traffic

• D. Valdembri, P.T. Caswell, K.I. Anderson, J.P. Schwarz, I. König, E. Astanina, F. Caccavari, J.C. Norman, M.J. Humphries, F. Bussolino, and G. Serini. Neuropilin−1/GIPC1 Signaling Regulates α5β1 Integrin Traffic and Function in Endothelial Cells. PLoS Biology 2009, 7:e1000025.
• C. Sandri, F. Caccavari, D. Valdembri, C. Camillo, S. Veltel, M. Santambrogio, L. Lanzetti, F. Bussolino, J. Ivaska, and G. Serini. The R-Ras/RIN2/Rab5 complex controls endothelial cell adhesion and morphogenesis via active integrin endocytosis and Rac signaling. Cell Res. 2012, 22:1479-1501.
• G. Mana, F. Clapero, E. Panieri, V. Panero, R. T. Böttcher, H.Y. Tseng, F. Saltarin, E. Astanina, K.I. Wolanska, M. R. Morgan, M.J. Humphries, M.M. Santoro, G. Serini*, and D. Valdembri*. PPFIA1 drives active α5β1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis. Nat. Commun. 2016, 7: 13546. *Shared senior and corresponding authorship.

2. Stephanie Miserey-Linkei (Institut Curie, PSL Research University)

• Title of talk: “Getting out the Golgi complex thanks to the RAB6 GTPase”

Dr Miserey-Linkei is a talented senior researcher in the group of Prof. Bruno Goud in Institut Curie. She investigates the mechanisms regulating cellular transport with a focus on unravelling the role of Rab GTPases, the Golgi network and microtubules in this important biological process.

Selected publications (Stephanie Miserey-Linkei):

• Miserey-Lenkei S, Bousquet H, Pylypenko O, Bardin S, Dimitrov A, Bressanelli, G, Bonifay R, Fraisier V, Guillou C, Bougeret C, Houdusse A, Echard A, Goud B. Coupling fission and exit of RAB6 vesicles at Golgi hotspots through kinesin-myosin interactions. Nat Commun. 2017, 8(1):1254.
• Patwardhan A, Bardin S, Miserey-Lenkei S, Larue L, Goud B, Raposo G, Delevoye C. Routing of the RAB6 secretory pathway towards the lysosome related organelle of melanocytes. Nat Commun. 2017, 8:15835.
• Miserey-Lenkei S, Colombo MI. Small RAB GTPases Regulate Multiple Steps of Mitosis. Front Cell Dev Biol. 2016, 4:2. Review.
• Delevoye C, Miserey-Lenkei S, Montagnac G, Gilles-Marsens F, Paul-Gilloteaux P, Giordano F, Waharte F, Marks MS, Goud B, Raposo G. Recycling endosome tubule morphogenesis from sorting endosomes requires the kinesin motor KIF13A. Cell Rep. 2014, 6(3):445-54.
• Al Awabdh S, Miserey-Lenkei S, Bouceba T, Masson J, Kano F, Marinach-Patrice C, Hamon M, Emerit MB, Darmon M. A new vesicular scaffolding complex mediates the G-protein-coupled 5-HT1A receptor targeting to neuronal dendrites. J Neurosci. 2012, 32(41):14227-41.
• Miserey-Lenkei S, Waharte F, Boulet A, Cuif MH, Tenza D, El Marjou A, Raposo G, Salamero J, Héliot L, Goud B, Monier S. Rab6-interacting protein 1 links Rab6 and Rab11 function. Traffic. 2007, 8(10):1385-403.
• Miserey-Lenkei S, Couëdel-Courteille A, Del Nery E, Bardin S, Piel M, Racine V, Sibarita JB, Perez F, Bornens M, Goud B. A role for the Rab6A’ GTPase in the inactivation of the Mad2-spindle checkpoint. EMBO J. 2006, 25(2):278-89.

Tomas Strandin, University of Helsinki
The role of endothelial cells in hantavirus pathogenesis.

Host: Pekka Kolehmainen

Tomas Strandin, University of Helsinki
The role of endothelial cells in hantavirus pathogenesis.

Host: Pekka Kolehmainen

Jari Nuutila, Päivi Jalava-Karvinen, University of Turku and University Hospital Turku
Flow cytometry in infection diagnostics.

Host: Sisko Tauriainen.

Jari Nuutila, Päivi Jalava-Karvinen, University of Turku and University Hospital Turku
Flow cytometry in infection diagnostics.

Host: Sisko Tauriainen.

Csilla Sipeky: Aggressive prostate cancer: from genetic basis to clinical translation

Pauliina Hartiala: Lymfactin trial – Combined adenoviral VEGF-C and lymph node transfer treatment for patients with breast cancer treatment associated lymphedema

Csilla Sipeky: Aggressive prostate cancer: from genetic basis to clinical translation

Pauliina Hartiala: Lymfactin trial – Combined adenoviral VEGF-C and lymph node transfer treatment for patients with breast cancer treatment associated lymphedema

Welcome words by the Dean, coffee, cake and sparkling wine. Music by Aura Brass Band in Medisiina D lobby

Opening programme (in Finnish) on Monday, 8 October at 2pm in Sakari Alhopuro lecture hall in Medisiina D

KUN LÄÄKETIEDE KOHTASI POLITIIKAN – YHTEISKUNNALLISIA PAINEITA LÄÄKETIETEELLISEN TIEDEKUNNAN VAIHEISSA
Vesa Vares, Professor of Political History, UTU

LÄÄKETIETEELLISEN TIEDEKUNNAN TÄHTIHETKIÄ JA TAITEKOHTIA
Timo Niitemaa, M.Soc.Sci, Communications Officer (emeritus), UTU

TULEVAISUUDEN NÄKYMIÄ
Markku Wilenius, Professor of Futures Studies UTU

Welcome to join the festive activities!

Programme of the festival week

Welcome words by the Dean, coffee, cake and sparkling wine. Music by Aura Brass Band in Medisiina D lobby

Opening programme (in Finnish) on Monday, 8 October at 2pm in Sakari Alhopuro lecture hall in Medisiina D

KUN LÄÄKETIEDE KOHTASI POLITIIKAN – YHTEISKUNNALLISIA PAINEITA LÄÄKETIETEELLISEN TIEDEKUNNAN VAIHEISSA
Vesa Vares, Professor of Political History, UTU

LÄÄKETIETEELLISEN TIEDEKUNNAN TÄHTIHETKIÄ JA TAITEKOHTIA
Timo Niitemaa, M.Soc.Sci, Communications Officer (emeritus), UTU

TULEVAISUUDEN NÄKYMIÄ
Markku Wilenius, Professor of Futures Studies UTU

Welcome to join the festive activities!

Programme of the festival week

Eleonora Mäkelä: Novel diagnostic markers in AML

Mari Suominen: Radium-223 dichloride as a dual inhibitor of the vicious cycle and tumor growth in breast and prostate cancer bone metastasis models

Eleonora Mäkelä: Novel diagnostic markers in AML

Mari Suominen: Radium-223 dichloride as a dual inhibitor of the vicious cycle and tumor growth in breast and prostate cancer bone metastasis models

Programme here

Programme here

Dr. Hans Hendriks, Hendriks Pharmaceutical Consulting

Coffee served at 14:45

Hans Hendriks, Ph.D., held positions in Cell Biology and Immunology at the Vrije Universiteit (Amsterdam, The Netherlands). After 17 years he joined the New Drug Development Office (now part of INC Research), Europe’s foremost oncology Contract Research Organisation (Amsterdam, The Netherlands), gaining 12 years experience leading international drug discovery and development collaborations. In addition, he served in various drug development and drug evaluation committees of the EORTC, Cancer Research UK and US National Cancer Institute, and held for 8 years a position in the Executive Board of the EORTC Biological Therapeutics Development Group.

He established Hendriks Pharmaceutical Consulting January 2000, an independent consultancy company providing services to small companies and biotechs in Oncology R&D. He is co-founder of the Biotherapy Development Association (Germany, 2001) and served on the Scientific Advisory Board of a German biotech company (2001-2003). He was the National Network Representative for The Netherlands in the Council of the European Association for Cancer Research (EACR), period 2013-2018, and received a  honorary EACR membership as of 2018.

From 2002-2006 Dr. Hendriks acted as Project Technical Assistant to the European Commission (DG Research) in the 5th Framework Programme (FP) overseeing 20 cancer-related EU-funded projects, served as expert evaluator in 5th, 6th, 7th FP and H2020 of the EU and acted as Administrative Manager for the FP6 CompuVac project (June 2008-October 2009). In addition, he assisted Austrian, Dutch, Italian, and Slovenian consortia in the preparation and submission of grant applications for the European Union’s 7th FP, H2020 and the Innovative Medicines Initiative 2.

He was successful in bringing the telomere targeting agent KML001 from early stage preclinical research to Phase I clinical studies (CCR 2008;14:4593-602) and is co-inventor of a US patent application (2009).

Hendriks Pharmaceutical Consulting is member of the Competence Network Life Science (www.conelis.org), an association of selected life science experts that provides top-tier consulting services to the pharmaceutical industry. It is a network of highly qualified and independent experts who can be contracted individually or as part of an interdisciplinary team.

Selected publications

Hendriks. H. et al., Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative, British Journal of Cancer, 2017.

Peters, GJ., Govaerts, A-S., Hendriks, H. for the EORTC-pharmacology and molecular mechanism group. The role of pharmacology in anticancer drug development, ADMET, 2018

Dr. Hans Hendriks, Hendriks Pharmaceutical Consulting

Coffee served at 14:45

Hans Hendriks, Ph.D., held positions in Cell Biology and Immunology at the Vrije Universiteit (Amsterdam, The Netherlands). After 17 years he joined the New Drug Development Office (now part of INC Research), Europe’s foremost oncology Contract Research Organisation (Amsterdam, The Netherlands), gaining 12 years experience leading international drug discovery and development collaborations. In addition, he served in various drug development and drug evaluation committees of the EORTC, Cancer Research UK and US National Cancer Institute, and held for 8 years a position in the Executive Board of the EORTC Biological Therapeutics Development Group.

He established Hendriks Pharmaceutical Consulting January 2000, an independent consultancy company providing services to small companies and biotechs in Oncology R&D. He is co-founder of the Biotherapy Development Association (Germany, 2001) and served on the Scientific Advisory Board of a German biotech company (2001-2003). He was the National Network Representative for The Netherlands in the Council of the European Association for Cancer Research (EACR), period 2013-2018, and received a  honorary EACR membership as of 2018.

From 2002-2006 Dr. Hendriks acted as Project Technical Assistant to the European Commission (DG Research) in the 5th Framework Programme (FP) overseeing 20 cancer-related EU-funded projects, served as expert evaluator in 5th, 6th, 7th FP and H2020 of the EU and acted as Administrative Manager for the FP6 CompuVac project (June 2008-October 2009). In addition, he assisted Austrian, Dutch, Italian, and Slovenian consortia in the preparation and submission of grant applications for the European Union’s 7th FP, H2020 and the Innovative Medicines Initiative 2.

He was successful in bringing the telomere targeting agent KML001 from early stage preclinical research to Phase I clinical studies (CCR 2008;14:4593-602) and is co-inventor of a US patent application (2009).

Hendriks Pharmaceutical Consulting is member of the Competence Network Life Science (www.conelis.org), an association of selected life science experts that provides top-tier consulting services to the pharmaceutical industry. It is a network of highly qualified and independent experts who can be contracted individually or as part of an interdisciplinary team.

Selected publications

Hendriks. H. et al., Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative, British Journal of Cancer, 2017.

Peters, GJ., Govaerts, A-S., Hendriks, H. for the EORTC-pharmacology and molecular mechanism group. The role of pharmacology in anticancer drug development, ADMET, 2018

Dr. Wah Ing Goh, the Agency for Science, Technology and Research (A*STAR) Microscopy Platform

Host: Camilo Guzman

Dear all,

We would like to invite you to a special seminar by   (https://www.a-star.edu.sg/imb/Tech-Platforms/IMB-Microscopy-Unit) in Singapore. Her seminar is entitled “The A*STAR Microscopy Platform and SingaScope – a microscopy core facility network for Singapore”. The seminar will take place in the TBC seminar room on the 5th Floor (Bio 5034a) and it is scheduled for Thursday 16th of August at 2:00 PM.

Dr. Goh is visiting the TBC as part of the “Job Shadowing International Program” of the Global BioImaging project and he will be shadowing our activities in bio imaging and promoting and active exchange between the Agency for Science, Technology and Research (A*STAR) and our Finnish ALM Node of Euro-BioImaging

For detailed information please see attached PDF file.

See you all there!

Dr. Wah Ing Goh, the Agency for Science, Technology and Research (A*STAR) Microscopy Platform

Host: Camilo Guzman

Dear all,

We would like to invite you to a special seminar by   (https://www.a-star.edu.sg/imb/Tech-Platforms/IMB-Microscopy-Unit) in Singapore. Her seminar is entitled “The A*STAR Microscopy Platform and SingaScope – a microscopy core facility network for Singapore”. The seminar will take place in the TBC seminar room on the 5th Floor (Bio 5034a) and it is scheduled for Thursday 16th of August at 2:00 PM.

Dr. Goh is visiting the TBC as part of the “Job Shadowing International Program” of the Global BioImaging project and he will be shadowing our activities in bio imaging and promoting and active exchange between the Agency for Science, Technology and Research (A*STAR) and our Finnish ALM Node of Euro-BioImaging

For detailed information please see attached PDF file.

See you all there!

Klaus Hedman, University of Helsinki

Host: Sisko Tauriainen

Klaus Hedman, University of Helsinki

Host: Sisko Tauriainen

FinLAS (Suomen koe-eläintieteen yhdistys ry) järjestää kevätseminaarin 18.5.2018 Turussa. Seminaari on tarkoitettu kaikille koe-eläinten parissa työskenteleville, koe-eläinalan ammattilaisille, tutkijoille ja opiskelijoille. Tapahtuma tarkempi ohjelma on tässä, ja kevätseminaarissa pääsemme kuulemaan koe-eläinkeskuksen johtajan Ulla-Marjut Jaakkolan läksiäisluennon.

Ilmoittautuminen: https://www.webropolsurveys.com/S/B9CD93BC3F165132.par

Lisätietoa: Emrah Yatkin (emryat@utu.fi)

FinLAS (Suomen koe-eläintieteen yhdistys ry) järjestää kevätseminaarin 18.5.2018 Turussa. Seminaari on tarkoitettu kaikille koe-eläinten parissa työskenteleville, koe-eläinalan ammattilaisille, tutkijoille ja opiskelijoille. Tapahtuma tarkempi ohjelma on tässä, ja kevätseminaarissa pääsemme kuulemaan koe-eläinkeskuksen johtajan Ulla-Marjut Jaakkolan läksiäisluennon.

Ilmoittautuminen: https://www.webropolsurveys.com/S/B9CD93BC3F165132.par

Lisätietoa: Emrah Yatkin (emryat@utu.fi)

Matti Waris, University of Turku

Host: Ilkka Julkunen

Matti Waris, University of Turku

Host: Ilkka Julkunen

Finnish Society for Bioinformatics is arranging a yearly Bioinformatics day, and the program includes lectures, poster session and workshops. The topics of the lectures are dealing with current bioinformatics research including both biosciences and computational modeling. This event gathers together people working with bioinformatics, both from universities and from companies around Finland.

Program of the event is available here.

Registration to the event from here.

Finnish Society for Bioinformatics is arranging a yearly Bioinformatics day, and the program includes lectures, poster session and workshops. The topics of the lectures are dealing with current bioinformatics research including both biosciences and computational modeling. This event gathers together people working with bioinformatics, both from universities and from companies around Finland.

Program of the event is available here.

Registration to the event from here.

Ilkka Julkunen, University of Turku

Host: Laura Kakkola

Ilkka Julkunen, University of Turku

Host: Laura Kakkola

Prof. John Lemasters
GlaxoSmithKline Distinguished Endowed Chair
Director, Center for Cell Death, Injury & Regeneration
Departments of Drug Discovery & Biomedical Sciences and Biochemistry & Molecular Biology
Medical University of South Carolina, USA

Host: Eeva-Liisa Eskelinen (eeva-liisa.eskelinen@utu.fi)
In case you wish to meet with Prof. Lemasters, please contact the host.

Dr. Lemasters’ research interests include the cellular and molecular mechanisms underlying toxic, hypoxic and ischemia-reperfusion injury to liver and heart. His laboratory applies new techniques of laser scanning confocal and multiphoton microscopy to characterize the physiology of single living cells, including the assessment of ion homeostasis, chelatable iron, mitochondrial function, electrical potentials, oxygen and nitrogen free radical formation, membrane permeability and other biochemical parameters during the pathogenesis of lethal cell injury.

 Selected publications

DeHart DN, Fang D, Heslop K, Li L, Lemasters JJ, Maldonado EN. Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol. 2018 Feb;148:155-162. doi: 10.1016/j.bcp.2017.12.022. Epub 2017 Dec 28.

Maldonado EN, DeHart DN, Patnaik J, Klatt SC, Gooz MB, Lemasters JJ. ATP/ADP turnover and import of glycolytic ATP into mitochondria in cancer cells is independent of the adenine nucleotide translocator. J Biol Chem. 2017 Oct 13;292(41):16969. doi: 10.1074/jbc.A116.734814.

Teplova VV, Kruglov AG, Kovalyov LI, Nikiforova AB, Fedotcheva NI, Lemasters JJ. Glutamate contributes to alcohol hepatotoxicity by enhancing oxidative stress in mitochondria. J Bioenerg Biomembr. 2017 Jun;49(3):253-264. doi: 10.1007/s10863-017-9713-0. Epub 2017 May 6.

Liu Q, H Rehman, Y Krishnasamy, RG Schnellmann, JJ Lemasters and Z Zhong. Improvement of liver injury and survival by JNK2 and iNOS deficiency in liver transplants from cardiac death mice. J Hepatol 2015, 63:68-74.

Prof. John Lemasters
GlaxoSmithKline Distinguished Endowed Chair
Director, Center for Cell Death, Injury & Regeneration
Departments of Drug Discovery & Biomedical Sciences and Biochemistry & Molecular Biology
Medical University of South Carolina, USA

Host: Eeva-Liisa Eskelinen (eeva-liisa.eskelinen@utu.fi)
In case you wish to meet with Prof. Lemasters, please contact the host.

Dr. Lemasters’ research interests include the cellular and molecular mechanisms underlying toxic, hypoxic and ischemia-reperfusion injury to liver and heart. His laboratory applies new techniques of laser scanning confocal and multiphoton microscopy to characterize the physiology of single living cells, including the assessment of ion homeostasis, chelatable iron, mitochondrial function, electrical potentials, oxygen and nitrogen free radical formation, membrane permeability and other biochemical parameters during the pathogenesis of lethal cell injury.

 Selected publications

DeHart DN, Fang D, Heslop K, Li L, Lemasters JJ, Maldonado EN. Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol. 2018 Feb;148:155-162. doi: 10.1016/j.bcp.2017.12.022. Epub 2017 Dec 28.

Maldonado EN, DeHart DN, Patnaik J, Klatt SC, Gooz MB, Lemasters JJ. ATP/ADP turnover and import of glycolytic ATP into mitochondria in cancer cells is independent of the adenine nucleotide translocator. J Biol Chem. 2017 Oct 13;292(41):16969. doi: 10.1074/jbc.A116.734814.

Teplova VV, Kruglov AG, Kovalyov LI, Nikiforova AB, Fedotcheva NI, Lemasters JJ. Glutamate contributes to alcohol hepatotoxicity by enhancing oxidative stress in mitochondria. J Bioenerg Biomembr. 2017 Jun;49(3):253-264. doi: 10.1007/s10863-017-9713-0. Epub 2017 May 6.

Liu Q, H Rehman, Y Krishnasamy, RG Schnellmann, JJ Lemasters and Z Zhong. Improvement of liver injury and survival by JNK2 and iNOS deficiency in liver transplants from cardiac death mice. J Hepatol 2015, 63:68-74.

Nicholas Kurniawan (PhD; assistant professor in biomedical engineering) and Aref Saberi (BSc) from the Eindhoven University of Technology (TU/e) will present their research as well as research and study opportunities available at their university next week at ÅAU Cell Biology.

Host: prof. Cecilia Sahlgren

13.15-14:00 Dr. Nicholas Kurniawan, Assistant professor in biomedical engineering, Eindhoven University of Technology (TU/e): Mechanobiology and tissue engineering

Dr. Kurniawan will present his research focused on the biophysical and mechanobiological aspects of cell-matrix interactions and related applications in regenerative medicine. In his research he combines expertise in biopolymer physics, cell biomechanics, and cytoskeletal rheology.

14:15-15:00 Aref Saberi, Eindhoven University of Technology (TU/e): Research activities and MSc programmes at Eindhoven University of Technology

An overview of research activities, educational programmes and student life at TU/e. The presentation is directed especially at students and researchers interested in doing an exchange abroad.

Kurniawan and Saberi will also give a lecture on stem cells and mechanosignaling on the ÅAU Stem cells course (223001.0) at 10-12 on the same day (in Kurssalen). Everyone interested is welcome to take part in the lecture as well.

Nicholas Kurniawan (PhD; assistant professor in biomedical engineering) and Aref Saberi (BSc) from the Eindhoven University of Technology (TU/e) will present their research as well as research and study opportunities available at their university next week at ÅAU Cell Biology.

Host: prof. Cecilia Sahlgren

13.15-14:00 Dr. Nicholas Kurniawan, Assistant professor in biomedical engineering, Eindhoven University of Technology (TU/e): Mechanobiology and tissue engineering

Dr. Kurniawan will present his research focused on the biophysical and mechanobiological aspects of cell-matrix interactions and related applications in regenerative medicine. In his research he combines expertise in biopolymer physics, cell biomechanics, and cytoskeletal rheology.

14:15-15:00 Aref Saberi, Eindhoven University of Technology (TU/e): Research activities and MSc programmes at Eindhoven University of Technology

An overview of research activities, educational programmes and student life at TU/e. The presentation is directed especially at students and researchers interested in doing an exchange abroad.

Kurniawan and Saberi will also give a lecture on stem cells and mechanosignaling on the ÅAU Stem cells course (223001.0) at 10-12 on the same day (in Kurssalen). Everyone interested is welcome to take part in the lecture as well.

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

Juha Vuononvirta, Imperial College of London

Host: Alex-Mikael Barkoff

Juha Vuononvirta, Imperial College of London

Host: Alex-Mikael Barkoff

Minna Poranen, University of Helsinki

Host: Veijo Hukkanen

Minna Poranen, University of Helsinki

Host: Veijo Hukkanen

Arno Hänninen, Univeristy of Turku

Host: Raine Toivonen

Arno Hänninen, Univeristy of Turku

Host: Raine Toivonen

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Karolina Louvanto, University Hospital of Turku, University of Turku

Host: Stina Syrjänen

Karolina Louvanto, University Hospital of Turku, University of Turku

Host: Stina Syrjänen

Jaana Vuopio, University of Turku

Host: to be announced

Jaana Vuopio, University of Turku

Host: to be announced

Tiina Nokireki, Finnish Food Safety Authority

Host: Tytti Vuorinen

Tiina Nokireki, Finnish Food Safety Authority

Host: Tytti Vuorinen

BioCity research programme seminar, organized jointly by LIFESPAN and Receptor Programme and Turku Brain and Mind Center

Prof. Ulrik Gether, University of Copenhagen
The dopamine transporter: a key player in psychostimulant addiction and dopaminergic pathologies

Dr. Volker Eulenburg, University Hospital Leipzig, Clinics for Anaesthesiology and Intensive Care Medicine
Glycine transporter function in retina and dorsal horn – GlyT1 as a major regulator of glycine dependent neurotransmission

Host: Mika Scheinin (mschein@utu.fi)

Coffee/tea will be served at 15:00

BioCity research programme seminar, organized jointly by LIFESPAN and Receptor Programme and Turku Brain and Mind Center

Prof. Ulrik Gether, University of Copenhagen
The dopamine transporter: a key player in psychostimulant addiction and dopaminergic pathologies

Dr. Volker Eulenburg, University Hospital Leipzig, Clinics for Anaesthesiology and Intensive Care Medicine
Glycine transporter function in retina and dorsal horn – GlyT1 as a major regulator of glycine dependent neurotransmission

Host: Mika Scheinin (mschein@utu.fi)

Coffee/tea will be served at 15:00

Minna Niemelä, Turku Centre for Biotechnology

Host: Raine Toivonen

Minna Niemelä, Turku Centre for Biotechnology

Host: Raine Toivonen

This seminar is cancelled

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

This seminar is cancelled

Tapio Lönnberg, Turku Centre for Biotechnology

Host: Raine Toivonen

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Manu Tamminen, University of Turku

Host: Kirsi Gröndahl-Yli-Hannuksela

Prof. John Marshall, Barts Cancer Institute, London, UK

Prof. John Marshall, Barts Cancer Institute, London, UK

Host: Johanna Ivaska

Prof. John Marshall has been studying the biology of tumour invasion for the last 25 years with a particular interest in the contributions made by the principal cell-matrix adhesion molecules called integrins. Prof Marshall’s group have identified integrin αvβ6, an epithelial-specific integrin not detectable on most normal tissues, as an important new therapeutic target in many cancers. In addition to understanding the function of the αvβ6 receptor in cancer, his group recently launched a clinical trial, in collaboration with Imanova to test the efficacy of an αvβ6-specific peptide for imaging solid cancers.

Selected publications

Raab-Westphal S, Marshall JF, Goodman SL. Integrins as Therapeutic Targets: Successes and Cancers. 2017 Cancers (Basel) 9(9).

Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RM, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. (2017) Mol Ther. 25(1):259-273

Moore KM, Thomas GJ, Duffy SW et al. Therapeutic targeting of integrin αvβ6 in breast cancer. (2014) J Natl Cancer Inst vol. 106, (8)

Allen MD, Thomas GJ, Clark S et al. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. (2014) Clin Cancer Res (2) 344-357

Morgan MR, Jazayeri M, Ramsay AG, Thomas GJ, Boulanger MJ, Hart IR, Marshall JF. Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion. (2011) Oncogene 30(12):1422-35

Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, Hart IR and Marshall JF. High resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin αvβ6. (2010) J Path. 222:52-63

You are warmly welcome to the Turku Cancer Research Society’s Christmas Seminar!

Topic of the seminar will be colorectal cancer and we have speakers presenting both basic research and clinical aspects.

Program
16.00 Welcome
PhD Thesis of the Year Award
-Break for snacks and drinks-
17.00 Annika Ålgars (Turku University Hospital)
“An oncologists perspective to CRC and a glimpse into own research data”
17.30 Diana Toivola (Åbo Akademi University)
“Colorectal cancer – Keratins in disease mechanism and disease modeling”
17.50 Elli Narvi (University of Turku)
“Response to EGFR inhibition plus oxaliplatin is determined by the sequence of administration in colorectal cancer”

You are warmly welcome to the Turku Cancer Research Society’s Christmas Seminar!

Topic of the seminar will be colorectal cancer and we have speakers presenting both basic research and clinical aspects.

Program
16.00 Welcome
PhD Thesis of the Year Award
-Break for snacks and drinks-
17.00 Annika Ålgars (Turku University Hospital)
“An oncologists perspective to CRC and a glimpse into own research data”
17.30 Diana Toivola (Åbo Akademi University)
“Colorectal cancer – Keratins in disease mechanism and disease modeling”
17.50 Elli Narvi (University of Turku)
“Response to EGFR inhibition plus oxaliplatin is determined by the sequence of administration in colorectal cancer”

MIKRO Seminars of Infection Biology and Infectious Diseases

Tuija Kantala, University of Turku

Host: Matti Waris

MIKRO Seminars of Infection Biology and Infectious Diseases

Tuija Kantala, University of Turku

Host: Matti Waris

Adjunct Prof. Timo Myöhänen, Drug Research Program, University of Helsinki

Host: Jukka Westermarck

Timo Myöhänen got his PhD (Pharmacology) in 2008 at University of Kuopio, and thereafter had post-doctoral visits in University of Antwerp (Belgium) and Georgetown University (Washington DC, USA) in 2010 and 2012. Dr. Myöhänen established his research group into Division of Pharmacology and Pharmacotherapy in University of Helsinki in 2011, got docentship in pharmacology in 2012 and is currently holding an Academy of Finland Research Fellow position. His research has focused on impact of a serine protease, prolyl oligopeptidase (PREP) and its pharmacological inhibition, on aggregation and toxicity of alpha-synuclein, a possible key player in cellular toxicity on Parkinson’s disease. Recent studies of Myöhänen lab have shown that PREP inhibitors can reduce the aggregation of alpha-synuclein and also enhance its clearance from cells by accelerating autophagy.

Lab website: http://blogs.helsinki.fi/prepinneuro/

Adjunct Prof. Timo Myöhänen, Drug Research Program, University of Helsinki

Host: Jukka Westermarck

Timo Myöhänen got his PhD (Pharmacology) in 2008 at University of Kuopio, and thereafter had post-doctoral visits in University of Antwerp (Belgium) and Georgetown University (Washington DC, USA) in 2010 and 2012. Dr. Myöhänen established his research group into Division of Pharmacology and Pharmacotherapy in University of Helsinki in 2011, got docentship in pharmacology in 2012 and is currently holding an Academy of Finland Research Fellow position. His research has focused on impact of a serine protease, prolyl oligopeptidase (PREP) and its pharmacological inhibition, on aggregation and toxicity of alpha-synuclein, a possible key player in cellular toxicity on Parkinson’s disease. Recent studies of Myöhänen lab have shown that PREP inhibitors can reduce the aggregation of alpha-synuclein and also enhance its clearance from cells by accelerating autophagy.

Lab website: http://blogs.helsinki.fi/prepinneuro/

Prof. Robert Viger, Laval University, Quebec, Canada

Prof. Robert Viger, Laval University, Quebec, Canada

Hosts: Nafis Rahman and Jorma Toppari

Anniina Rintala, University of Turku

Host: Jaana Vuopio

Anniina Rintala, University of Turku

Host: Jaana Vuopio

Florian Freudenberg, Translational Psychiatry Laboratory, Department of Psychiatry, Frankfurt University Hospital

Host: Michael Courtney

Florian Freudenberg, Translational Psychiatry Laboratory, Department of Psychiatry, Frankfurt University Hospital

Host: Michael Courtney

Prof. Duane A. Compton, Geisel School of Medicine at Dartmouth, Hanover, USA

Prof. Duane A. Compton, Geisel School of Medicine at Dartmouth, Hanover, USA

Host: Sofia Pruikkonen

Prof. Andrew Cant, Institute of Cellular Medicine, University of Newcastle, UK

Prof. Andrew Cant, Institute of Cellular Medicine, University of Newcastle, UK

Host: Ville Peltola

MIKRO Seminars of Infection Biology and Infectious Diseases

Johanna Ivaska, University of Turku

Host: Raine Toivonen

MIKRO Seminars of Infection Biology and Infectious Diseases

Johanna Ivaska, University of Turku

Host: Raine Toivonen

MIKRO Seminars of Infection Biology and Infectious Diseases

Ausra Domanska, University of Helsinki

Host: Petri Susi

MIKRO Seminars of Infection Biology and Infectious Diseases

Ausra Domanska, University of Helsinki

Host: Petri Susi

Prof. Mihai Netea, Faculty of Medical Sciences, Radboud University, Nijmegen, Netherlands

Prof. Mihai Netea, Faculty of Medical Sciences, Radboud University, Nijmegen, Netherlands:

Host: Riitta Lahesmaa ( rilahes@utu.fi )

SmartBIO Annual Meeting will be arranged on Monday November 6th 2017 in Kankaisten Linna (Kankaistentie 57, 21250 Masku). SmartBIO is one of the seven BioCity Turku Research Programmes for the years 2016-2020. In this one-day meeting the scientific program (all in English) includes two invited lecturers from industry partners and fifteen-minute talks from SmatBIO team members.

The registration is now open until Oct 29^th https://link.webropolsurveys.com/S/6116624FED0228CAYou can also find the registration from the SmartBIO web pages, together with the tentative program and more detailed information.
http://smartbio.fi/registration-smartbio-annual-meeting-2017-open

If you have any questions regarding the meeting please don’t hesitate to contact Maija Lespinasse (miholm@utu.fi).

SmartBIO Annual Meeting will be arranged on Monday November 6th 2017 in Kankaisten Linna (Kankaistentie 57, 21250 Masku). SmartBIO is one of the seven BioCity Turku Research Programmes for the years 2016-2020. In this one-day meeting the scientific program (all in English) includes two invited lecturers from industry partners and fifteen-minute talks from SmatBIO team members.

The registration is now open until Oct 29^th https://link.webropolsurveys.com/S/6116624FED0228CAYou can also find the registration from the SmartBIO web pages, together with the tentative program and more detailed information.
http://smartbio.fi/registration-smartbio-annual-meeting-2017-open

If you have any questions regarding the meeting please don’t hesitate to contact Maija Lespinasse (miholm@utu.fi).

Patrick Lewis, Reading School of Pharmacy, Reading, United Kingdom

Host: Eleanor Coffey

Patrick Lewis, Reading School of Pharmacy, Reading, United Kingdom

Host: Eleanor Coffey

Prof. Michael Hottiger, Department of Molecular Mechanisms of Disease, University of Zürich, Zürich, Switzerland

Prof. Michael Hottiger, Department of Molecular Mechanisms of Disease, University of Zürich, Zürich, Switzerland:

Host: Arto Pulliainen

The Hottiger-laboratory studies molecular regulatory mechanisms of inflammation, with special focus on the role of post-translation modifications in inflammatory signaling. They have contributed to the identification of protein ADP-ribosylation as a crucial process in the cellular response to detrimental stimuli, be it through genotoxicity, oxidative or metabolic stress, or excessive inflammation. Their current work focuses on the following questions: (i) Are ADP-ribosylation patterns cell-type specific or stimulus-specific, i.e. are there specific patterns that are associated with specific cell-physiological conditions? (ii) What are the modifiers (writer, binders, erasers) involved in those patterns? How can we specifically interfere with their activity to modulate the patterns? (iii) What are the regulatory mechanisms in ADP-ribosylation? How is the type and quantity of ADP-ribosylation patterns regulated? (iv) What are the downstream events of ADP-ribosylation, i.e. how does ADP-ribosylation alter the function of specific proteins and what is the effect on cell physiology? Most recently, the Hottiger-laboratory has studied the patterns of ADP-ribosylation using new systems biology approaches such as ADP-ribose specific high-resolution and quantitative mass spectrometry.

Website: http://www.dmmd.uzh.ch/en/research/hottiger.html

Selected publications:

Bisceglie L, Bartolomei G and Hottiger MO (2017) ADP-ribose-specific chromatin-affinity purification for investigating genome-wide or locus-specific chromatin ADP-ribosylation. Nature Protocols Sep;12(9):1951-1961.

Bilan V, Selevsek N, Kistemaker HAV, Abplanalp J, Feurer R, Filippov DV and Hottiger MO (2017) New quantitative mass spectrometry approaches reveal different ADP-ribosylation phases dependent on the levels of oxidative stress. Molecular & Cellular Proteomics May;16(5):949-958.

Bilan V, Leutert M, Nanni P, Panse C, Hottiger MO (2017) Combining Higher-Energy collision dissociation and electron-transfer/higher energy collision dissociation fragmentation in a product-dependent manner confidently assigns proteomewide ADP-ribose acceptor Sites. Analytical Chemistry Feb 7;89(3):1523-1530.

Martello R, Leutert M, Jungmichel S, Bilan V, Larsen SC, Young C, Hottiger MO and Nielsen ML (2016) Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue. Nature Communications Sep 30;7:12917. doi:

Leutert M, Pedrioli DML and Hottiger MO (2016) Identification of PARP-specific ADP-ribosylation targets reveals a regulatory function for ADP-ribosylation in transcription elongation. Molecular Cell Jul 21;63(2):181-183.

Hottiger MO (2015) SnapShot: ADP-ribosylation signaling. Molecular Cell Jun 18;58(6):1134-1134.e1.

Associate Professor Sven Nelander, Uppsala University, Uppsala, Sweden

 Receptor Program Seminar

Host: Jukka Westermarck (jukwes(at)utu.fi)

****
Sven Nelander is an Associate Professor at the Department of Immunology, Genetics and Pathology and Science for Life Laboratory at Uppsala University. His research group focuses on integrated approaches to cancer intervention, combining computational and experimental methods. A key diagnostic focus is GBM. Sven Nelander received his PhD in 2005 at the University of Gothenburg and trained as a postdoc at Memorial Sloan Kettering Cancer Center, NY (Sander lab). He joined Uppsala University in 2012.

Associate Professor Sven Nelander, Uppsala University, Uppsala, Sweden

 Receptor Program Seminar

Host: Jukka Westermarck (jukwes(at)utu.fi)

****
Sven Nelander is an Associate Professor at the Department of Immunology, Genetics and Pathology and Science for Life Laboratory at Uppsala University. His research group focuses on integrated approaches to cancer intervention, combining computational and experimental methods. A key diagnostic focus is GBM. Sven Nelander received his PhD in 2005 at the University of Gothenburg and trained as a postdoc at Memorial Sloan Kettering Cancer Center, NY (Sander lab). He joined Uppsala University in 2012.

Prof. Mads Gyrd-Hansen, Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK:

Host: Annika Meinander (annika.meinander(at)abo.fi) (Receptor)
**************

The Gyrd-Hansen laboratory studies molecular mechanisms governing pro-inflammatory signalling during innate immune responses. Through this, they aim to understand the molecular mechanisms that on one hand protect against pathogens, but that also contribute to chronic inflammation, tumor development and cancer progression. A central focus of the lab is to elucidate the role and regulation of non-degradative ubiquitin modifications in these processes. Ultimately, they aim to identify ubiquitin-handling factors that can be targeted to modulate inflammation and antagonize cancer. Professor Gyrd-Hansen’s recent work has focused on the role of Met1-linked ubiquitin chains (also known as linear ubiquitin chains) in inflammatory signaling. These chains are generated by the Linear UBiquitin Assembly Complex (LUBAC), which is a key component of inflammatory signaling pathways, including those activated downstream of the cytoplasmic PRRs NOD1 and NOD2 that serve as sensors for intracellular bacteria. They have uncovered and characterised several factors that regulate the function of LUBAC in signaling. Future work in the group will focus on elucidating the function, regulation and interplay of individual ubiquitin chain types (of which there are at least eight) in the cellular response to infection.

Website: http://www.ludwig.ox.ac.uk/mads-gyrd-hansen

Selected publications:

Gyrd-Hansen M. All roads lead to ubiquitin. Cell Death Differ. 2017 Jul;24(7):1135-1136. doi: 10.1038/cdd.2017.93.

Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH, Wagstaff J, Volkmar N, Christianson JC, Kessler BM, Freund SM, Komander D, Gyrd-Hansen M. SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. Mol Cell. 2016 Sep 15;63(6):990-1005. doi: 10.1016/j.molcel.2016.08.001.

Hrdinka M, Fiil BK, Zucca M, Leske D, Bagola K, Yabal M, Elliott PR, Damgaard RB, Komander D, Jost PJ, Gyrd-Hansen M. CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling. Cell Rep. 2016 Mar 29;14(12):2846-58. doi: 10.1016/j.celrep.2016.02.062.

Fiil BK, Gyrd-Hansen M. Met1-linked ubiquitination in immune signalling. FEBS J. 2014 Oct;281(19):4337-50. doi: 10.1111/febs.12944.

Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost PJ, Ehl S, Mailand N, Gyrd-Hansen M. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med. 2013 Aug;5(8):1278-95. doi: 10.1002/emmm.201303090.

Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S, Mailand N, Choudhary C, Komander D, Gyrd-Hansen M. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell. 2013 Jun
27;50(6):818-830. doi: 10.1016/j.molcel.2013.06.004.

Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ, Gyrd-Hansen M. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012 Jun 29;46(6):746-58. doi: 10.1016/j.molcel.2012.04.014.

Prof. Mads Gyrd-Hansen, Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK:

Host: Annika Meinander (annika.meinander(at)abo.fi) (Receptor)
**************

The Gyrd-Hansen laboratory studies molecular mechanisms governing pro-inflammatory signalling during innate immune responses. Through this, they aim to understand the molecular mechanisms that on one hand protect against pathogens, but that also contribute to chronic inflammation, tumor development and cancer progression. A central focus of the lab is to elucidate the role and regulation of non-degradative ubiquitin modifications in these processes. Ultimately, they aim to identify ubiquitin-handling factors that can be targeted to modulate inflammation and antagonize cancer. Professor Gyrd-Hansen’s recent work has focused on the role of Met1-linked ubiquitin chains (also known as linear ubiquitin chains) in inflammatory signaling. These chains are generated by the Linear UBiquitin Assembly Complex (LUBAC), which is a key component of inflammatory signaling pathways, including those activated downstream of the cytoplasmic PRRs NOD1 and NOD2 that serve as sensors for intracellular bacteria. They have uncovered and characterised several factors that regulate the function of LUBAC in signaling. Future work in the group will focus on elucidating the function, regulation and interplay of individual ubiquitin chain types (of which there are at least eight) in the cellular response to infection.

Website: http://www.ludwig.ox.ac.uk/mads-gyrd-hansen

Selected publications:

Gyrd-Hansen M. All roads lead to ubiquitin. Cell Death Differ. 2017 Jul;24(7):1135-1136. doi: 10.1038/cdd.2017.93.

Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH, Wagstaff J, Volkmar N, Christianson JC, Kessler BM, Freund SM, Komander D, Gyrd-Hansen M. SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. Mol Cell. 2016 Sep 15;63(6):990-1005. doi: 10.1016/j.molcel.2016.08.001.

Hrdinka M, Fiil BK, Zucca M, Leske D, Bagola K, Yabal M, Elliott PR, Damgaard RB, Komander D, Jost PJ, Gyrd-Hansen M. CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling. Cell Rep. 2016 Mar 29;14(12):2846-58. doi: 10.1016/j.celrep.2016.02.062.

Fiil BK, Gyrd-Hansen M. Met1-linked ubiquitination in immune signalling. FEBS J. 2014 Oct;281(19):4337-50. doi: 10.1111/febs.12944.

Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost PJ, Ehl S, Mailand N, Gyrd-Hansen M. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med. 2013 Aug;5(8):1278-95. doi: 10.1002/emmm.201303090.

Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S, Mailand N, Choudhary C, Komander D, Gyrd-Hansen M. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell. 2013 Jun
27;50(6):818-830. doi: 10.1016/j.molcel.2013.06.004.

Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ, Gyrd-Hansen M. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012 Jun 29;46(6):746-58. doi: 10.1016/j.molcel.2012.04.014.

For symposium program, click here.

Register latest Oct 22nd at: https://link.webropolsurveys.com/S/C1C0722937CB171E

For symposium program, click here.

Register latest Oct 22nd at: https://link.webropolsurveys.com/S/C1C0722937CB171E

Prof. Ville Kaila, Department of Chemistry, Technical University of Munich, Germany

Prof. Ville Kaila, Department of Chemistry, Technical University of Munich, Germany

Host: Paula Mulo

Description of research:

The research of Prof. Ville Kaila is focused on enzymatic and biomimetic catalysts for energy conversion. These processes are studied in respiratory and photosynthetic enzymes, but also in non-biological systems such as water-splitting molecular catalysts and molecular capsules. Prof. Kaila applies and develops powerful computational methodology ranging from ab initio quantum chemical techniques, hybrid quantum mechanics/classical mechanics (QM/MM) and subsystems methods, to large-scale classical molecular dynamics simulations, free-energy and continuum approaches.

Prof. Kaila will describe his recent work on the respiratory Complex I, and he will discuss how combination of experiments and multi-scale molecular simulations can provide a powerful methodology to obtain a molecular-level understanding of the structure, energetics, and dynamics of energy-capturing proteins, and how such methods can further be employed to engineer and design new proteins with desired target functions.

Selected publications:

Sharma V, Belevich G, Gamiz-Hernandez AP, Róg T, Vattulainen I, Wikström M, Hummer G, Kaila VRI (2015) Redox-Induced Activation of the Proton Pump in the Respiratory Complex I Proc. Natl. Acad. Sci. USA 112:11571-11576.

Kmita K, Wirth C, Warnau J, Guerrero-Castillo S, Hunte C, Hummer G, Kaila VRI, Zwicker K, Brandt U, Zickermann V. (2015) Accessory NUMM (NDUFS6) subunit harbors a Zn-binding site and is essential for biogenesis of mitochondrial complex I.  Proc. Natl. Acad. Sci. USA 112:5685-5690.

Boczek EE, Reefschläger LG, Dehling M, Struller T, Häusler E, Seidl A, Kaila VRI, Buchner J (2014) Conformational processing of oncogenic v-Src kinase by Hsp90. Proc. Natl. Acad. Sci. USA 112: E3189-3198.

Wikström M, Sharma V, Kaila VRI, Hosler J, Hummer G (2015) New perspectives on proton pumping in cellular respiration. Chem. Rev. 115, 2196-2221.

Kaila VRI , Schotte F, Hyun S-C, Hummer G, Anfinrud PA (2014) Reconciling contradictions in time-resolved x-ray structures of early intermediates in the photocycle of photoactive yellow protein Nature Chem 6:258-259.

Kaila VRI ,  Wikström M, Hummer G (2014) Electrostatics, Hydration, and Proton Transfer Dynamics in the Membrane Domain of Respiratory Complex I. Proc Natl Acad Sci USA 111, 6988-6993.

Schotte F, Hyun S-C,  Kaila VRI, Kamikubo H, Dashdorja N, Henry E, Graber T, Henning R, Wulff M, Hummer G, Kataoka M, Anfinruda PA (2012) Picosecond Photobiology: Watching a Signaling Protein Function in Real Time via Time-resolved Laue Crystallography. Proc Natl Acad Sci USA 109, 19256-19261.

Robert Lyle, Oslo University Hospital and University of Oslo, Norway

Host: Riikka Lund

Robert Lyle, Oslo University Hospital and University of Oslo, Norway

Host: Riikka Lund

Päivi Saavalainen, University of Helsinki
Host: Jorma Ilonen

Päivi Saavalainen, University of Helsinki
Host: Jorma Ilonen

Program

10.00     Coffee
10.15     Professor Noel Morgan, University of Exeter Medical School, UK: “Type 1 diabetes; evidence for disease heterogeneity”
11.00     Dr Sarah Richardson, University of Exeter Medical School, UK: “Is Type 1 Diabetes ‘Going Viral’?”
11.45     Dr. Mark Russell, Islet Biology Exeter, UK: “JAK/STAT Signalling in the Pathogenesis of Type 1 Diabetes”

Organised by:

The Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology
Turku Centre for LIFESPAN Research

Program

10.00     Coffee
10.15     Professor Noel Morgan, University of Exeter Medical School, UK: “Type 1 diabetes; evidence for disease heterogeneity”
11.00     Dr Sarah Richardson, University of Exeter Medical School, UK: “Is Type 1 Diabetes ‘Going Viral’?”
11.45     Dr. Mark Russell, Islet Biology Exeter, UK: “JAK/STAT Signalling in the Pathogenesis of Type 1 Diabetes”

Organised by:

The Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology
Turku Centre for LIFESPAN Research

Prof. Antti Poso, University of Eastern Finland, School of Pharmacy; Distinguished Guest Professor at the University of Tübingen in Germany

Host: Outi Salo-Ahen (outi.salo-ahen(at)abo.fi)

Prof. Antti Poso’s main research interest has been computer-aided drug design and early hit/lead identification and optimization. He did his post-doctoral research as a Humboldt-fellow in Düsseldorf with Prof. H.-D. Höltje (1997-1998) and after returning to Finland he started his own molecular modeling group. One of his first major research topics was to identify and optimize sirtuin inhibitors, especially against Sirt2. His group has also contributed substantially to the design of new compounds targeting different proteins of the endogenous cannabinoid system, such as CB1 and CB2 receptors as well as MAGL and FAAH enzymes. In recent years, his interest has shifted mainly to anti-cancer and anti-infective drug design, although he is also active in projects aiming to find new therapies to age-related macular degeneration. Besides his position at the University of Eastern Finland, he has also worked at FIMM (Helsinki) with Prof. Kallioniemi and since 2012 as a Guest Professor at the University of Tübingen (Germany) with professors Zender and Laufer.

About the seminar topic:

The seminar talk will discuss three separate projects in anti-cancer drug discovery. The introduction will give a brief overview of the methods used in Kuopio and Tübingen. The first case study is about a ribosomal drug targeting project and how early computational work is mandatory for a successful druggable target identification. The other two projects (targeting a kinase and DNA replication proteins) are both currently in the late lead-optimization phase.

Prof. Antti Poso, University of Eastern Finland, School of Pharmacy; Distinguished Guest Professor at the University of Tübingen in Germany

Host: Outi Salo-Ahen (outi.salo-ahen(at)abo.fi)

Prof. Antti Poso’s main research interest has been computer-aided drug design and early hit/lead identification and optimization. He did his post-doctoral research as a Humboldt-fellow in Düsseldorf with Prof. H.-D. Höltje (1997-1998) and after returning to Finland he started his own molecular modeling group. One of his first major research topics was to identify and optimize sirtuin inhibitors, especially against Sirt2. His group has also contributed substantially to the design of new compounds targeting different proteins of the endogenous cannabinoid system, such as CB1 and CB2 receptors as well as MAGL and FAAH enzymes. In recent years, his interest has shifted mainly to anti-cancer and anti-infective drug design, although he is also active in projects aiming to find new therapies to age-related macular degeneration. Besides his position at the University of Eastern Finland, he has also worked at FIMM (Helsinki) with Prof. Kallioniemi and since 2012 as a Guest Professor at the University of Tübingen (Germany) with professors Zender and Laufer.

About the seminar topic:

The seminar talk will discuss three separate projects in anti-cancer drug discovery. The introduction will give a brief overview of the methods used in Kuopio and Tübingen. The first case study is about a ribosomal drug targeting project and how early computational work is mandatory for a successful druggable target identification. The other two projects (targeting a kinase and DNA replication proteins) are both currently in the late lead-optimization phase.

Prof. W. Brent Derry, The Hospital for Sick Children and Department of Molecular Genetics, University of Toronto

Host: Annika Meinander (ÅAU Cell Biology and Receptor Programme)

The broad goal of Derry’s research is to understand how genes that are mutated in various diseases function in vivo. He uses the powerful genetics and functional genomics tools of the model organism Caenorhabditis elegans to understand how tumour suppressors and oncogenes control cell survival, genome stability and organism development. He is particularly interested in how cells communicate with one another to sculpt organs and make life or death decisions when challenged with stresses, such as chemotherapy and radiation. Derry also has a robust research program that is focused on understanding the mechanistic basis of the human neurovascular disease cerebral cavernous malformations (CCM). He is collaborating with an international team of scientists and clinicians to discover drugs that can be used to prevent the onset of CCM in humans.

Selected publications:
Pal, S., Lant, B., Yu, B., Tian, R., Tong, J., Krieger, J.R., Moran, M.F., Gingras, A.C., & Derry, W. B. CCM-3 Promotes C. elegans germline development by regulating vesicle trafficking cytokinesis and polarity. (2017) Current Biology. 27(6): 868-876.

Eroglu, M. & Derry, W.B. (2016) Your neighbours matter – non-autonomous control of apoptosis in development and disease. Cell Death and Differentiation. 23(7): 1110-1118.

Mateo, A.R, Kessler, Z., Jolliffe, A.K., McGovern, O., Yu, B., Nicolucci, A., Yanowitz, J.L. & Derry, W.B. (2016) The p53-like protein CEP-1 is required for meiotic fidelity in C. elegans. Current Biology. 26(9): 1148-1158.

Lant B, Yu B, Goudreault M, Holmyard D, Knight JD, Xu P, Zhao L, Chin K, Wallace E, Zhen M, Gingras AC, Derry WB. (2015) CCM-3/STRIPAK promotes seamless tube extension through endocytic recycling. Nature Communications. 6: 6449.

Baruah, A., Chang, H., Hall, M., Yuan, J., Gordon, S., Johnson, E., Shtessel, L.L., Yee, C., Hekimi, S., Derry, W.B., & Lee, S.S. (2014). CEP1, the Caenorhabditis elegans p53 homolog, mediates opposing longevity outcomes in mitochondrial electron transport chain mutants. PLoS Genetics. 10(2): e1004097.

Perrin, A.J., Gunda, M., Yu, B., Yen, K., Ito, S., Forster, S., Young, J., Tissenbaum, H.A. & Derry, W.B. (2013). Noncanonical control of C. elegans germline apoptosis by the insulin/IGF-1 and Ras/MAPK signaling pathways. Cell Death and Differentiation. 20(1): 97-107.

Ross, A.J., Li, M., Yu, B., Gao, M.X. & Derry, W.B. (2011). The EEL-1 ubiquitin ligase promotes DNA damage-induced germ cell apoptosis in C. elegans. Cell Death and Differentiation. 18(7): 1140-1149.

Ito, S., Greiss, S., Gartner, A. & Derry, W.B. (2010). Cell-nonautonomous regulation of C. elegans germ cell death by kri-1. Current Biology. 20(4): 333-338.

Gao, X. Liao, E., Yu, B., Wang, Y., Zhen, M. & Derry, W.B. (2008). The SCFFSN-1 ubiquitin ligase controls CEP-1/p53-dependent apoptosis in Caenorhabditis elegans. Cell Death and Differentiation. 15(6): 1054-1062.

Quevedo, C., Kaplan, D.R. & Derry, W.B. (2007). AKT-1 regulates DNA-damage induced germline apoptosis in C. elegans. Current Biology. 17(3): 286-292.

Prof. W. Brent Derry, The Hospital for Sick Children and Department of Molecular Genetics, University of Toronto

Host: Annika Meinander (ÅAU Cell Biology and Receptor Programme)

The broad goal of Derry’s research is to understand how genes that are mutated in various diseases function in vivo. He uses the powerful genetics and functional genomics tools of the model organism Caenorhabditis elegans to understand how tumour suppressors and oncogenes control cell survival, genome stability and organism development. He is particularly interested in how cells communicate with one another to sculpt organs and make life or death decisions when challenged with stresses, such as chemotherapy and radiation. Derry also has a robust research program that is focused on understanding the mechanistic basis of the human neurovascular disease cerebral cavernous malformations (CCM). He is collaborating with an international team of scientists and clinicians to discover drugs that can be used to prevent the onset of CCM in humans.

Selected publications:
Pal, S., Lant, B., Yu, B., Tian, R., Tong, J., Krieger, J.R., Moran, M.F., Gingras, A.C., & Derry, W. B. CCM-3 Promotes C. elegans germline development by regulating vesicle trafficking cytokinesis and polarity. (2017) Current Biology. 27(6): 868-876.

Eroglu, M. & Derry, W.B. (2016) Your neighbours matter – non-autonomous control of apoptosis in development and disease. Cell Death and Differentiation. 23(7): 1110-1118.

Mateo, A.R, Kessler, Z., Jolliffe, A.K., McGovern, O., Yu, B., Nicolucci, A., Yanowitz, J.L. & Derry, W.B. (2016) The p53-like protein CEP-1 is required for meiotic fidelity in C. elegans. Current Biology. 26(9): 1148-1158.

Lant B, Yu B, Goudreault M, Holmyard D, Knight JD, Xu P, Zhao L, Chin K, Wallace E, Zhen M, Gingras AC, Derry WB. (2015) CCM-3/STRIPAK promotes seamless tube extension through endocytic recycling. Nature Communications. 6: 6449.

Baruah, A., Chang, H., Hall, M., Yuan, J., Gordon, S., Johnson, E., Shtessel, L.L., Yee, C., Hekimi, S., Derry, W.B., & Lee, S.S. (2014). CEP1, the Caenorhabditis elegans p53 homolog, mediates opposing longevity outcomes in mitochondrial electron transport chain mutants. PLoS Genetics. 10(2): e1004097.

Perrin, A.J., Gunda, M., Yu, B., Yen, K., Ito, S., Forster, S., Young, J., Tissenbaum, H.A. & Derry, W.B. (2013). Noncanonical control of C. elegans germline apoptosis by the insulin/IGF-1 and Ras/MAPK signaling pathways. Cell Death and Differentiation. 20(1): 97-107.

Ross, A.J., Li, M., Yu, B., Gao, M.X. & Derry, W.B. (2011). The EEL-1 ubiquitin ligase promotes DNA damage-induced germ cell apoptosis in C. elegans. Cell Death and Differentiation. 18(7): 1140-1149.

Ito, S., Greiss, S., Gartner, A. & Derry, W.B. (2010). Cell-nonautonomous regulation of C. elegans germ cell death by kri-1. Current Biology. 20(4): 333-338.

Gao, X. Liao, E., Yu, B., Wang, Y., Zhen, M. & Derry, W.B. (2008). The SCFFSN-1 ubiquitin ligase controls CEP-1/p53-dependent apoptosis in Caenorhabditis elegans. Cell Death and Differentiation. 15(6): 1054-1062.

Quevedo, C., Kaplan, D.R. & Derry, W.B. (2007). AKT-1 regulates DNA-damage induced germline apoptosis in C. elegans. Current Biology. 17(3): 286-292.

Akira Takeda, University of Turku

Host: Raine Toivonen

Akira Takeda, University of Turku

Host: Raine Toivonen

Simo Nikkari, Center for Military Medicine

Host: Alex-Mikael Barkoff

Simo Nikkari, Center for Military Medicine

Host: Alex-Mikael Barkoff

Paolo Pesaresi and Carlotta Peracchio, Università degli studi di Milano

Paolo Pesaresi and Carlotta Peracchio, Università degli studi di Milano

Dr. Marc Therrien, Université de Montréal, Montreal, Quebec, Canada

Dr. Marc Therrien, Université de Montréal, Montreal, Quebec, Canada

Host: Daniel Abankwa

Turku Cancer Research Society is pleased to announce a daylong seminar on drug discovery and development entitled ‘ACADEMIC CANCER DRUG DEVELOPMENT: Challenges and successes’.

This seminar with distinguished speakers from Finland, Europe and overseas will take place on Monday September 25, 2017 in Congress Centre Mauno, Turku. For more details and registration please visit http://cancerresearch.utu.fi.

Turku Cancer Research Society is pleased to announce a daylong seminar on drug discovery and development entitled ‘ACADEMIC CANCER DRUG DEVELOPMENT: Challenges and successes’.

This seminar with distinguished speakers from Finland, Europe and overseas will take place on Monday September 25, 2017 in Congress Centre Mauno, Turku. For more details and registration please visit http://cancerresearch.utu.fi.

Prof. Frank Claessens, Laboratory of Molecular Endocrinology, Leuven, Belgium

Host: Matti Poutanen

Prof. Frank Claessens, Laboratory of Molecular Endocrinology, Leuven, Belgium

Host: Matti Poutanen

Subhash K. Tripathi, University of Turku

Subhash K. Tripathi, University of Turku

Satu Pekkala, University of Jyväskylä

Host: Eveliina Munukka

Satu Pekkala, University of Jyväskylä

Host: Eveliina Munukka

Dr. Eugene V Koonin, National Center for Biotechnology, Information National Library of Medicine, NIH, Bethesda, USA

Dr. Eugene V Koonin, National Center for Biotechnology Information, National Library of Medicine, NIH, Bethesda, USA

Host: Pere Puigbo (pepuav(at)utu.fi)

Professor James Golden, University California, San Diego:
”Broad-Host-Range Genetic Tools for Cyanobacteria and Heterologous Expression of Natural Products”

Professor Susan Golden, Distinguished Professor Director, University California, San Diego:
”A Day in the Life of a Cyanobacterium: integrating temporal and environmental information”

Professor James Golden, University California, San Diego:
”Broad-Host-Range Genetic Tools for Cyanobacteria and Heterologous Expression of Natural Products”

Professor Susan Golden, Distinguished Professor Director, University California, San Diego:
”A Day in the Life of a Cyanobacterium: integrating temporal and environmental information”

Professor Pirjo Nuutila, University of Turku

Chair: Jorma Toppari

Coffee will be served at 12.00
Seminar 12.15-13.00 is followed by discussion

Professor Pirjo Nuutila, University of Turku

Chair: Jorma Toppari

Coffee will be served at 12.00
Seminar 12.15-13.00 is followed by discussion

The newly formed Turku Metabolomics facility is pleased to announce a seminar to celebrate its opening.

9:30 Welcome and coffee
10:00 Matej Orešič (UTU) – Metabolomics in biomedical research: platforms, challenges, opportunities
10:10 Alex Dickens (UTU) – Biomarkers/Turku core facility
10:30 Jari Sinkkonen (UTU) – Tissue NMR for metabolomics at the NMR Instrument Centre
10:45 Mika Scheinin (UTU/Turku University Hospital) – Pharmacokinetics and verification of drug exposure
11:00 Dawei Geng (Örebro University, Sweden) – Metabolomics at Örebro University and collaboration with Turku Metabolomics facility
11:20 Linda Ahonen (Steno Diabetes Center Copenhagen, Denmark) – Lipidomics with automatized QC – case study: NIST ring trial
11:40 Kati Hanhineva (University of Eastern Finland) – Untargeted metabolomics for nutrition and food research
12:00 Reception and adjourn

The newly formed Turku Metabolomics facility is pleased to announce a seminar to celebrate its opening.

9:30 Welcome and coffee
10:00 Matej Orešič (UTU) – Metabolomics in biomedical research: platforms, challenges, opportunities
10:10 Alex Dickens (UTU) – Biomarkers/Turku core facility
10:30 Jari Sinkkonen (UTU) – Tissue NMR for metabolomics at the NMR Instrument Centre
10:45 Mika Scheinin (UTU/Turku University Hospital) – Pharmacokinetics and verification of drug exposure
11:00 Dawei Geng (Örebro University, Sweden) – Metabolomics at Örebro University and collaboration with Turku Metabolomics facility
11:20 Linda Ahonen (Steno Diabetes Center Copenhagen, Denmark) – Lipidomics with automatized QC – case study: NIST ring trial
11:40 Kati Hanhineva (University of Eastern Finland) – Untargeted metabolomics for nutrition and food research
12:00 Reception and adjourn

Dr. Lorna Young, Laboratory of Prof. Harry Higgs, Geisel School of Medicine, Dartmouth College, USA

Dr. Bert Dhondt, University of Ghent, Belgium

Host: Jyrki Heino (jyrki.heino(at)utu.fi)

Mario Pagano, University of Padova, Italy

Host: Jukka Westermarck

Maijaliisa Erkkola, Dep. of Food and Environmental Sciences, University of Helsinki

Host: Kirsi Laitinen ( kirsi.laitinen@utu.fi )

Michael Brenan, Research Associate, 1CellBio

Host: Hongbo Zhang

Dr. Jan Lammerding, Nancy E. and Peter C. Meinig School of Biomedical Engineering, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, USA

Host: Pekka Taimen

Pirjo Merilahti University of Turku

Host: Sisko Tauriainen

Dr. Vinagolu K. Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center, New York, NY

Host: Johanna Tuomela (jomitu@utu.fi)

Professor David F. Stern, Department of Pathology, Yale University, New Haven, USA

Host: Klaus Elenius

Thorsten Joeris, Lund University, Sweden

Host: Raine Toivonen

Juhani Aakko University of Turku

Host: Arno Hänninen

Prof. Steven Pals, University of Amsterdam, The Netherlands

Host: Sirpa Jalkanen

Professor Benjamin G. Neel, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA

Host: Jukka Westermarck

Teemu Smura University of Helsinki

Host: Sisko Tauriainen

Professor Pirkko Härkönen, University of Turku

Host: Kirsi Laitinen

Professor Brian C. Freeman, Department of Cell & Developmental Biology, University of Illinois, Urbana, Illinois, USA

Host: Lea Sistonen

Professor Hongquan Zhang, Department of Anatomy, Histology and Embryology and Laboratory of Molecular Cell Biology and Tumor

Host: Jyrki Heino

Pirjo Merilahti, University of Turku

Host: Sisko Tauriainen

Professor Dietrich Kabelitz, Department of Immunology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

Host: Jorma Määttä

Professor Henk Stunnenberg, Department of Molecular Biology, Radboud University, Nijmegen, The Netherlands

Host: Riitta Lahesmaa

Academy professor Virpi Lummaa, University of Turku, Turku, Finland

Host: Jyrki Heino

Professor Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Host: Anna Knittle

Dr. Marco Fritzsche, MRC Human Immunology Unit, Weatherall Institute for Molecular Medicine, University of Oxford, Oxford, UK

Host: Pieta Mattila

Tero Ahola, University of Helsinki

Host: Petri Susi

Professor Jussi Taipale, Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

Host: Jukka Westermarck

Professor Wouter de Laat, Hubrecht Institute, Utrecht, The Netherlands

Host: Riitta Lahesmaa

Speaker: Dr. Julie Bouckaert, University of Lille, France

Speaker: Dr. Julie Bouckaert, University of Lille, France

Prof. Birgit Lane, Institute of Medical Biology and Skin Research Institute of Singapore, Nanyang Technological University, Singapore

Host: Diana Toivola

Dr. Thomas Lilley, Department of Biology, University of Turku & Bucknell University, Lewisburg, USA

Host: Päivi Koskinen

Programme.

Registration (latest on Monday, 5 December)

Programme.

Registration (latest on Monday, 5 December)

Programmme

Registration by 29.11. to contact-tcrs@lists.utu.fi

Please also indicate a possible special diet when registering.

Programmme

Registration by 29.11. to contact-tcrs@lists.utu.fi

Please also indicate a possible special diet when registering.

Siri Tähtinen, University of Helsinki

Host: Laura Kakkola

Prof. Moira O’Bryan, Monash University, Clayton, Victoria, Australia

Host: Anu Sironen

Pieta Mattila, University of Turku

Host: Jukka Alinikula

Prof. Michael McHeyzer-Williams, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, USA

Host: Liu Chengqian

Linnéa Linko, University of Turku

Host: Marianne Gunell

Adj. prof. Adolfo Rivero-Müller, Turku Centre for Biotechnology

Host: Päivi Koskinen

Prof. Ron van Schaik, Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands

Host: Csilla Sipeky

Elina Mäntylä, University of Jyväskylä

Host: Veijo Hukkanen

Olga Vitek, College of Science, College of Computer and Information Science, Northeastern University, Boston, USA

Host: Laura Elo

Olga Vitek, College of Science, College of Computer and Information Science, Northeastern University, Boston, USA

Host: Laura Elo

Pia Rantakari, University of Turku

Host: Eveliina Munukka

Dr. Niina Santio, Department of Biology, University of Turku

Host: Päivi Koskinen

Teemu Kallonen, Sanger Institute, UK

Host: Erkki Eerola

Anthony Chalmers, Institute of Cancer Sciences, University of Glasgow, Scotland, UK

Host: Jukka Westermarck

Prof. Jens Mittag, University of Lübeck, Lübeck, Germany

Host: Jukka Kero

Ulvi Gürsoy, University of Turku

Host: Eija Könönen

Applications of modern mass spectrometry in life sciences

 
Programme and registration (by October 24)

Applications of modern mass spectrometry in life sciences

 
Programme and registration (by October 24)

Adj. prof. Jussi Jäntti, VTT Synthetic Biology Group, Espoo

Host: Päivi Koskinen

Henna-Maria Uusitupa, University of Turku

Host: Eveliina Munukka

Professor Anne Ridley, King´s College London, UK

Host: Päivi Koskinen

Speaker: Adam Byron, Edinburgh Cancer Research UK Centre, University of Edinburgh, UK

Speaker: Adam Byron, Edinburgh Cancer Research UK Centre, University of Edinburgh, UK

Dr. Sophie Rousseaux, INSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France

Host: Noora Kotaja